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Abstract 
 
Background 
Alcohol related liver disease, including cirrhosis, is a major cause of death in the UK (Williams et 
al 2014). Liver disease is silent and usually presents late. FibroScan® is a non-invasive tool for 
measuring liver stiffness; an indicator for fibrosis/cirrhosis. Socially deprived patients with 
alcohol related liver disease are a “hard to engage” population (Watt 2013) therefore, simple 
screening methods may help early identification of liver disease.  
 
Aims 
1. Monitor uptake of FibroScan® in individuals accessing one community alcohol support 
service in a deprived area.  
2. Determine prevalence of undiagnosed fibrosis/cirrhosis in study sample.  
3. Monitor engagement following referral to specialist liver services. 
 
Method 
A prospective observational study recruited self-identified harmful drinkers between 
November 2014 and April 2015 for a liver FibroScan®. Participants with a FibroScan® reading of 
≥7.1kPa were referred to a nurse-led liver clinic for further investigations, results of which 
determined referral to a liver specialist in secondary care. Participants referred were monitored 
for engagement over 6 months. Descriptive statistics were used to determine prevalence of 
undiagnosed cirrhosis and to determine engagement.  
                                                                                                                              
Results  
Seventy-nine consented individuals participated, an uptake of 67% of those informed of the 
study (n=118). Of the 79 scans performed, three were unreliable leaving 76 participants. After 
scanning, 20/76 (26%) had a FibroScan® reading ≥7.1kPa requiring referral on to the nurse led 
clinic. All 20 (100%) engaged in further assessment. Of those, 12 required onward referral to 
specialist services. Subsequent compliance with specialist services in this sample (n=12) was ≥ 
90%. 
 
Conclusion 
This nurse-led intervention advances nursing practice in the field of Hepatology. It demonstrates 
high uptake and subsequent engagement in liver services, giving potential for early intervention 
and improved health outcomes in a previously considered hard to engage population (Watt 
2013). 
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Chapter 1: Introduction and Background  
1.01 Background to Study 
As a Hepatology nurse practitioner part of the author’s remit was to offer a hepatitis C 
treatment clinic in a multi-agency drug and alcohol support centre. This centre was situated in 
an area of the South of Scotland serving a population who, according to the Scottish Index of 
Multiple Deprivation (SIMD) (2016), were living in an area of high deprivation. This is a 
deprivation score devised according to a combination of seven variables. These include income, 
employment, health, education, housing, geographical access and crime. This drug and alcohol 
support centre served a population who, according to a combination of these seven variables, 
were amongst the most deprived 20% (decile 2) in Scotland and, in one area local to the 
support centre, the most deprived 5% (SIMD 2016). 
Over 90% of those infected with hepatitis C have acquired this through injecting drug use 
(Scottish Government 2015).  The author, therefore, was predominantly in contact with those 
attending the service for support with recovery from drugs, less so with those attending for 
support in recovery from alcohol. To redress the balance, this study was developed; in 
particular, to enable early identification of liver disease in a group considered to be at high risk 
through a history of heavy drinking. In this context, heavy drinking includes hazardous drinking 
which is defined as a level of consumption which increases a person’s risk of harm, harmful 
drinking which is a pattern of drinking already causing mental or physical damage and 
dependent drinking which is characterised by a strong desire to drink alcohol and difficulty 
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controlling its use (NICE 2010). This chapter explores the rationale for the study, in particular 
where it sits within the context of current policy drivers and will demonstrate the advanced
clinical practice skills (HEE 2019) of negotiation, influencing and leadership required by the 
author in analysis of the presenting problem and subsequent development of this initiative.  
Liver disease, including cirrhosis, is the third commonest cause of premature death in the UK 
and  mortality rates have  increased by approximately 500% in those under the age of 65 years 
since 1970 (Williams et al 2014). As such, it stands as an exception to the improved prognosis 
of those with other chronic illnesses such as chronic heart disease, stroke and some cancers in 
the under 65-year age group (Williams et al 2014). Deaths from chronic liver disease (CLD), 
including cirrhosis, increased globally between 1990 and 2013 from 1.5 million to 2.1 million 
(Cowie et al 2015). Within the European Union, standardised death rates from chronic liver 
disease were 13 per 105 in 2013, compared to 16 per 105 in the UK alone (WHO 2017). Alcohol 
related liver disease is a major contributor to morbidity and mortality in the UK. Current data 
for death rates due to alcohol in the UK, including alcohol related liver disease, report rates at 
14 per 105 since 2012 (ScotPHO 2017). This pattern is mirrored in Scotland, but with rates 
higher than in the rest of the UK. Death rates in men are 30 per 105 in Scotland and 18 per 105 
in England and for Scottish women are 13.3 per 105 and 9.1 per 105 in England (ONS 2017). In 
2015, mortality rates from CLD in Scotland in the most deprived decile were six times those of 
the least deprived (34 v 6 per 105) and morbidity rates were five times higher (435 v 88 per 105) 
(ScotPHO 2017). These data demonstrate the impact deprivation and health inequality issues 
have on CLD.  
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The World Health Organisation (WHO 2011) pledged to address health inequalities through 
developing strategies to promote effective partnerships with health and other sectors in 
achieving health through policies and actions on social determinants of health, specifically 
targeting vulnerable and high-risk groups. In Scotland, the Public Bodies (Joint Working) 
(Scotland) Bill (Scottish Government 2013) introduced a statutory duty for NHS Boards and 
Councils to integrate planning and delivery of health and social care services, strengthening the 
Scottish Government’s commitment to community-based anticipatory care (Audit Scotland 
2015). This care is to be provided jointly between the NHS, statutory and non-statutory social 
care providers with the aim of reducing the number of patients with long-term conditions being 
admitted to acute services (Audit Scotland 2015).  
1.02 Anatomy, Physiology and Pathophysiology of the Liver 
The liver is the largest solid organ and exocrine gland in the body. Weighing between 1.3-1.5kg, 
it accounts for approximately 2% of total body weight in an adult (Dancygier 2010). Located in 
the right upper quadrant of the abdominal cavity, beneath the diaphragm and protected by the 
rib cage the principle functions of the liver include protein synthesis, elimination of toxins, 
metabolism of carbohydrates, fats and proteins and storage of vitamins (Sargent 2009). 
Hepatocytes account for 60-70% of the total cell volume and 80% of the parenchymal volume 
and are capable of regeneration following a single injury. Blood supply to the liver is delivered 
by both the hepatic artery and the portal vein; with blood from the splanchnic area i.e. spleen, 
pancreas, stomach and intestine travelling to the liver via the portal vein (Dancygier 2010). 
Cirrhosis is characterised by diffuse nodules of regenerating hepatocytes surrounded by fibrous 
bands (Schuppan and Afdhal 2008, Sargent 2009) and is the potential end point for all causes of 
chronic liver disease (Pinzani, Rosselli and Zuckermann 2011).The most common causes of 
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cirrhosis in the developed world are Hepatitis C, alcohol and obesity (BASL, BSG 2009, Muir 
2015). While regeneration of liver tissue can occur following a single injury, sustained injury of 
hepatocytes leads to a process of scarring known as fibrosis. Fibrosis is often a precursor to 
cirrhosis if the cause of liver damage continues; both being part of a continuous spectrum of 
disease which can take 15-20 years to develop (Sargent 2009, Muir 2015). This process alters 
the normal liver architecture, causing increased intrahepatic resistance and reduced liver 
function (Muir 2015). While fibrosis is potentially reversible if the causal factor is removed, 
removal of the causal factor in cirrhosis may only prevent further progression to more severe 
disease (Schuppan and Afdhal 2008). Cirrhosis is classified into either compensated or 
decompensated disease. Patients with compensated cirrhosis are largely symptom free as the 
liver continues to sufficiently perform its vital functions. In those with decompensated cirrhosis 
extensive disease causes rapid decline in liver function manifesting in symptoms most 
commonly associated with portal hypertension; an increased blood pressure within the portal 
vein (Muir 2015, Pinzani, Rosselli and Zuckermann 2011, Tsochatizis, Bosch and Burroughs 
2014). These symptoms include ascites, the accumulation of fluid in the peritoneal cavity, 
encephalopathy or reversible cognitive impairment and non-obstructive jaundice (Sargent 
2009, Tsochatizis, Bosch and Burroughs 2014). 
Varices are asymptomatic, thin walled varicosities which can be formed by the development of 
collateral circulation between portal and systemic veins in response to an increase in portal 
pressure. They can develop in the oesophagus, stomach or rectum and are prone to rupture; a 
common cause of death in cirrhosis (Garcia-Tsao et al 2007, Sargent 2009). A variceal bleed 
carries around a 20% risk of mortality at 6 weeks (Muir 2015). All patients with cirrhosis should 
be offered screening for varices by endoscopy and prophylaxis, such as β-blocker therapy, 
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endoscopy band ligation and relevant follow up where appropriate (Tsochatzis, Bosch and 
Burroughs 2014).  
Progressive failure in detoxification of harmful substances passing from the splanchnic region 
through the portal vein causes an inflammatory state, which further accelerates disease 
progression; this, in conjunction with the hepatic stimulus for regeneration, provides ideal 
conditions for the development of hepatocellular carcinoma, a primary liver cancer (Pinzani, 
Rosselli and Zuckermann 2011). Surveillance for hepatoma by 6 monthly abdominal 
ultrasounds is recommended following a diagnosis of cirrhosis (EASL 2012) to improve the 
chance of early detection and successful treatment for those developing a tumour. 
While liver biopsy has been considered the gold standard diagnostic tool for cirrhosis (Castera 
2011) the invasive nature and risk of complications renders it unsuitable for use as a screening 
tool in a community setting.  A range of less invasive and non-invasive methods are available 
for the detection of fibrosis or cirrhosis, ranging from blood tests to more sophisticated 
methods including magnetic resonance imaging (MRI) (EASL-ALEH 2015). Of these, Liver 
Function Tests (LFTs) are the most commonly used blood tests.  Many of these tests rely on 
biochemical changes induced by altered liver function. In a large population based 
retrospective cohort study (n= 95,977) the link to outcomes of liver disease and mortality from 
a large database in primary care in Tayside from 1989 -2003 suggested that, while specificity of 
these tests was generally high, sensitivity was low with gamma glutamyl transferase (GGT) 
having the best sensitivity at 72% (Donnan et al 2007). In addition, interpretation of LFTs can be 
difficult and confusing for non-liver specialists.  Referral to specialist liver services often relies 
on the GP or health practitioner’s ability to interpret these results (Cook et al 2015). Due to the 
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size and cost of MRI equipment this method of screening is not appropriate in a non-acute 
setting.  
Cirrhosis develops because of increased fibrotic tissue and, as a result of this, liver stiffness 
increases (Muir 2015). Non-invasive assessment of liver fibrosis can use blood tests or imaging 
techniques. Hyaluronic acid (HA) is one such blood test used in specialist services but is non-
specific for the liver and can be raised in cases of arthritis (Adams 2011). Transient 
Elastography (TE), measured by a FibroScan® device is a non-invasive imaging test of fibrosis 
which is currently used in specialist centres as a screening and diagnostic tool for liver disease.  
It measures liver stiffness in kilopascals (kPa), using the propagation of an elastic shear wave 
through liver tissue from an ultrasound transducer probe. The probe is placed at the 8th to 
10th intercostal space in the mid axillary line while the patient is in the dorsal position, with 
their right arm in maximal abduction.  This is a quick, painless, non-invasive assessment for 
cirrhosis using liver stiffness measurements (LSM) which gives an instant result.  TE has been 
validated as a reliable marker for significant fibrosis and cirrhosis in a heavy alcohol using group 
(Nguyen-Khac et al 2008, Thiele et al 2015). TE readings range from 2.5 kPa to 75 kPa (Castera, 
Forns and Alberti 2008). The significance of the value of a TE reading varies depending on the 
aetiology of fibrosis or cirrhosis. The lower TE cut off for fibrosis and cirrhosis is debated with 
Thiele et al (2015) suggesting a lower cut off for significant fibrosis of 9.6 kPa and cirrhosis 19.7 
kPa in their alcohol using cohort. Castera, Forns and Alberti (2008) suggest that readings 
between 7.1-12.5kPa indicate significant fibrosis with values above 12.5kPa indicating cirrhosis. 
The FibroScan® device is available in portable form which, if used in a community setting, could 
reduce the need for attendance at specialist centres. The FibroScan® has been demonstrated to 
elicit equivalent readings when compared to a static FibroScan® (Parra-Ruiz et al 2014). Nurses 
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trained in the use of FibroScan® have been shown, through research, to elicit comparable 
readings to their medical colleagues (McCorry et al 2012). 
1.03 Factors Informing Critical Appraisal Through Searching the Literature 
A critical, focused review of the literature (Booth, Papaioannou and Sutton 2012) was 
conducted to establish the extent of work carried out, to date, with a review question “Is 
screening for liver disease in a community alcohol support setting with a portable FibroScan® 
device acceptable?”. This review was revisited throughout the study and on its completion, 
with details of the search strategy provided in Appendix 1. A key word search strategy, 
including the MeSH and CinAHL terms, “liver disease”, “liver cirrhosis”, “mass screening”, 
“alcoholic” and “transient elastography” was utilised, for the Medline and CinAHL databases. A 
wider key word search, including “liver fibrosis”, “liver stiffness”, “outreach”, “community” was 
used for the search engine “Discover” available online through Queen Margaret University 
library services. This software incorporates Medline, Cinahl, Psycinfo, SPORTdiscus, Science 
Citation Index, Science Direct, Social Sciences Citation Index. Each search was performed both 
under Boolean and “search all terms” conditions. In addition, the “Knowledge Network” 
available through NHS Lothian was utilised, which incorporates Ovid Embase and Ovid Medline. 
A search of the Cochrane database, for studies investigating community screening with a 
FibroScan®, was also carried out and the reference lists of relevant articles were examined for 
further articles of interest to this study.  
Inclusion criteria included all articles investigating screening for liver disease with a FibroScan® 
device in a community setting. Abstracts were excluded for review due to lack of availability of 
information to critique and a commentary by Castera (2011), while referred to elsewhere in 
this thesis, was excluded for the same reason. No time limit was set for this search as the 
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FibroScan® device is a relatively new invention, with historical reports of it use unlikely beyond 
fifteen years. This also accounts for the paucity of research in this area at the time of carrying 
out the literature search to inform this screening study, as much of the earlier literature had a 
focus on testing the validity of the FibroScan® device against other diagnostic techniques. 
The literature search found no published full text studies looking at the use of FibroScan® in a 
community alcohol support service prior to this study being carried out, several studies 
investigated its use either targeting PWID (People Who Inject Drugs) in the context of hepatitis 
C treatment or for use in primary care with the general population. Those studies targeting 
PWIDs in the community were of particular interest to the author due to their similarity in 
setting and the fact that they targeted a cohort seeking support in recovery from substance 
misuse; often considered “hard to engage”. In this respect, the author considered them to have 
some similar characteristics to the target group accessing the alcohol support service used in 
this study. Articles included for further critique included those by Roulot et al, (2010), Foucher 
et al (2009), Harmen et al (2015), Thurnheer et al (2015), Moessner et al (2011), Marshall et al 
2015 and Fabrellas et al (2013). An article which was excluded from further critique was 
Jacomet et al (2015) as, while the FibroScan® was not carried out in an acute setting, it was 
conducted in a prison setting; therefore, not comparable to recruitment in a community 
setting. 
A template outlining criteria for critique of the literature was designed (Appendix 2), informed 
by Wallace and Wray (2016). In total, seven full text articles were critiqued for this study. In 
commencing this critique, the research focus or research question for the study was recorded 
and its relevance to this screening study was assessed (Wallace and Wray 2016). This 
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assessment included investigation of the study rationale and in what respect this was relevant 
to the study which is the subject of this thesis. Research design and results were assessed, with 
the claims made being assessed for relevance to this piece of work. Results and claims were 
assessed for reliability and validity where possible and analysed for generalisability; in 
particular through assessment of the methods, sample size and rigour (Creswell 2014). Where 
the claims were supported or challenged by others’ work, this was assessed also and recorded 
in the critical review of the literature.  
1.04 Critical Review of the Literature 
In their prospective cross-sectional observational study, Moessner et al (2011) explored the use 
of FibroScan® for screening for liver disease in a cohort of PWIDs accessing all regional drug 
treatment centres in the city of Funen, Denmark, over a four-month period. It is unclear, from 
the text, how the potential participants were recruited. Members of the study team carried out 
the FibroScan® tests, with each technician completing 130 scans prior to carrying them out in 
this context. It is not documented whether interrater reliability checks were undertaken 
between technicians, making it difficult to assess the validity and generalisability of their 
findings (Creswell 2014).  This was combined with serum biological markers, tests for viral 
hepatitis and HIV in a relatively large sample size (n=450). Participants with results suggestive 
of significant fibrosis with a reading of ≥ 8kPa were referred to the department of infectious 
diseases for further evaluation. Those with a Liver Stiffness Measurement (LSM) ≥ 12kPa, 
indicating possible cirrhosis, were referred for liver biopsy as part of their management. The 
results indicate that, while FibroScan® is apparently effective in identifying patients with 
cirrhosis in this drug using population, they caution that management should not be based on 
one single measurement as, in 30% of participants who attended for liver biopsy, LSM were 
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reduced; a conclusion based on small cohort numbers (6/20). In addition, 42% (19/45) of 
participants with elevated LSM did not attend for liver biopsy, shedding some doubt on the 
reproducibility of this finding. According to Trabut et al (2015) LSM can decline rapidly during 
withdrawal in heavy drinkers. Alcohol consumption was not recorded longitudinally therefore, 
any variation in this, as a possible factor for change in LSM, was not determined. Lemoine et al 
(2014) found that LSM could be lower under fasting conditions. The initial FibroScan® 
measurement was not performed under fasting conditions, while participants were asked to 
fast for the subsequent reading taken at the time of biopsy. These factors could influence a 
lower subsequent LSM reading and have been considered in the development of this study 
where participants’ last alcohol intake was recorded, and they were asked to fast prior to 
attendance for the FibroScan®. 
In developing their theoretical framework of acceptability (TFA) for healthcare 
interventions, Sekhon, Cartwright and Francis (2018) suggest a conceptual definition of 
acceptability which acknowledges it is multi-faceted in nature and is determined by the extent 
to which those delivering the intervention and those receiving it anticipate or experience it to 
be appropriate. This is consistent with Sidani et al (2009) who suggest that perceived 
acceptability of an intervention, its suitability to a potential participant's lifestyle, its 
effectiveness and convenience are important factors influencing their uptake or participation. 
Sekhon, Cartwright and Francis (2018) identify seven components within the TFA which include 
how an individual feels about an intervention, its perceived effectiveness, and perceived 
amount of time or effort needed to participate. They also suggest an individual's confidence 
that the can carry out the behaviour needed to engage in the intervention is important in 
determining its acceptability, as is the extent to which the intervention fits with their value 
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system. The extent to which the participant understands the intervention is another important 
factor in assessing acceptability. Finally, the extent to which benefits must be given up to 
engage in the intervention is suggested as a component of TFA.  
In seeking to address the question of whether offering FibroScan® screening for liver disease is 
acceptable in a community alcohol service and, in the absence of literature specifically 
addressing screening in this setting, studies carried out by Foucher et al (2009) and Marshall et 
al (2015) were examined. Foucher et al (2009) and Marshall et al (2015) conducted prospective 
cohort studies targeted PWIDs, with a high risk of hepatitis C, and sought to evaluate screening 
for liver disease with a FibroScan® device in community and outreach settings, including drug 
support centres in France (Foucher et al (2009)) and Australia (Marshall et al (2015)). Both 
studies found screening with FibroScan® to be acceptable in reasonably large cohorts; n=298 
(Foucher et al 2009) and n=250 (Marshall et al 2015). 
Foucher et al (2009) measured “acceptance” of the FibroScan® through uptake. As this study 
was carried out in France, it is assumed that English is not the first language of the research 
team and interpretation of this as a measure of acceptability, where those who choose to 
engage in the intervention consider it to be appropriate (Sekhon, Cartwright and Francis 2017), 
should be taken with care. However, this study sought to assess the influence of FibroScan® 
screening on management of hepatitis C in a group where uptake of screening and treatment 
was low.  A FibroScan® test, with a low cut off threshold of 7.1kPa, was offered to consecutive 
drug users in two street-based outreach centres over a one-year period. In addition to the scan, 
participants were invited to complete a face to face questionnaire with trained outreach 
workers; it is not clear how and by whom, potential participants were invited or whether the 
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questionnaire had been validated. Following the FibroScan® each participant was invited, by a 
nurse, to supply a blood sample which included testing for hepatitis C. Following the scan and 
bloods all participants were offered a meeting with a Hepatologist in the centre. All drug users 
attending during the study period (n=298) agreed to have a FibroScan®; an uptake of 100%. 
Interestingly subsequent uptake of blood tests in this groups was 74% (221/298); higher than 
the authors’ expectation in this group considered hard to engage. During the study 10% (8/83) 
of those participants with hepatitis C commenced treatment; a group well known to the 
clinicians in the centre who, until the study had never accepted blood tests for hepatitis C. The 
authors conclude therefore that the uptake of screening and engagement with treatment for 
hepatitis C is a direct result of having the FibroScan® test. As this is a complex intervention it 
would seem reasonable to investigate this claim further. Participants were not described as 
self-selected and by stating they were “offered” a FibroScan® suggests that a verbal interaction 
took place with potential participants, either by staff at the outreach centre or the visiting 
research staff. This being the case, it is possible that the enthusiasm of either clinic or research 
staff may have had an influence on their motivation to have the scan. In addition, it is possible 
that information given to potential participants at time of recruitment may have influenced 
their decision to accept the intervention and subsequently influenced the outcome.  
In their prospective observational study, Marshall et al (2015) sought to enhance liver disease 
assessment in a drug and alcohol setting for PWIDs and aimed to determine the baseline 
knowledge of hepatitis C, the acceptability of FibroScan® or screening and willingness of 
participants to receive hepatitis C treatment among PWIDs participating in a liver health 
promotion campaign (LiveRLife). This study took place in New South Wales, Australia over a six-
month period. Participants were recruited from four centres based in the community; a 
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primary health care facility, two opiate substitution treatment centres and one medically 
supervised injecting centre. While this study was targeted at PWIDs, with a focus on 
engagement with hepatitis C treatment, the acceptability of FibroScan® in a community 
recovery support setting for vulnerable and an often hard to engage groups is of interest to this 
study targeting those with alcohol problems in a drug and alcohol setting. Participants were 
asked to complete a self-administered tablet-based questionnaire, pre-intervention which 
included questions regarding pre FibroScan® acceptability, based on a five-point Likert scale 
asking the question “How willing are you to have a FibroScan®?” with answers ranging from 
“definitely willing”, “somewhat willing”, “neither willing nor unwilling”, “somewhat unwilling” 
and “not at all willing”. A further question regarding acceptability was posed with answers 
ranging from “very acceptable”, “somewhat acceptable”, “neither acceptable nor 
unacceptable”, “somewhat unacceptable” and “not at all acceptable”. The intervention was 
carried out by a nurse and included the FibroScan®, a standard health check and review of 
medical history and, for some, a blood test for hepatitis C.  It is not stated within the text, what 
preparation for this research to ensure validity and reliability in collecting data, was undertaken 
by the nurse. It is, therefore, difficult to comment on this aspect of the study.  Prior to 
assessment 88% (221/250) of participants rated FibroScan® as “very acceptable”. Following 
assessment, 95% (232/244) rated it as “very acceptable” with 91% (222/244) “definitely 
willing” to receive FibroScan® again in the future and 93% (228/244) “definitely willing” to 
recommend FibroScan® to their peers. As part of their recruitment strategy, potential 
participants were offered a voucher to the value of $20 for their participation, which may have 
influenced their choice in taking part; possibly in their attitude towards the acceptability of the 
FibroScan®. The addition of the option for free text to the Likert scale questionnaire may have 
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enhanced the depth of information collected, regarding the acceptability, or otherwise, of the 
FibroScan®. However, this leaves interpretation of “acceptability” to the participants; with each 
potentially attributing a different meaning to this term. With reference to TFA, Sidani et al 
(2009) suggest asking more specific questions with regards to acceptability; questions which 
would elicit how participants felt regarding the appropriateness of the intervention, its 
suitability to their life style, effectiveness and convenience; which would have further 
enhanced understanding of participant’s views on the acceptability of the intervention further.  
In their prospective cohort study, Thurnheer et al (2015) also sought to evaluate an outreach 
programme offering FibroScan® to improve CLD assessment and compare disease prevalence 
between tertiary clinics, community clinics, clinics for PWIDs and regional clinics in Victoria, 
Australia. Results indicated that FibroScan® was feasible as a screening tool within a community 
setting and that, following further assessment, a higher level of more advanced liver disease 
was found in regional clinics. Hepatitis C was a known factor with this group, however while 
alcohol use was documented it was not quantified; an important consideration for further 
assessment as recent levels of alcohol intake can influence the FibroScan® result and each 
individual’s subsequent management (Thiele et al 2015). While higher incidence of disease 
within the regional clinics may suggest lower socioeconomic status with poor access to tertiary 
care this is not stated and cannot be assumed.  In addition, the cause of liver disease varied 
between the cohorts with those from community clinics more likely to be infected with 
hepatitis B from birth and of different ethnic origin with different lifestyle factors and therefore 
not directly comparable. Nonetheless, of interest to this study, is the higher prevalence of 
disease outwith the tertiary setting suggesting acute services may not be reaching those at 
most need and strengthens the case for screening for CLD in a community setting. 
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In the UK, Referral from a GP to a liver specialist is currently heavily reliant on an algorithm 
based solely on abnormal LFTs. Harmen et al (2015) sought to challenge this protocol in their 
prospective cross-sectional study across two GP practices in Nottingham. The aim of this study 
was to trial a new diagnostic algorithm where patients at most risk, through hazardous alcohol 
use, type 2 diabetes or a persistently elevated liver function enzyme (ALT) were identified from 
the GP database and invited to take part in the study. For those who participated (n=504), a 
blood-based biomarker test was offered; this varied according to the specific risk factors for 
each participant. Those at risk of alcohol related liver disease were assessed using AST/ALT 
ratio with a result >0.8 indicating increased risk, while patients with type 2 diabetes or 
persistently raised ALT were assessed using the BARD score (Ruffillo et al 2010), based on BMI 
and AST/ALT ratio with a result of ≥2 indicating increased risk.  Those who elicited a raised 
biomarker result were then offered a FibroScan® test within the primary care setting; these 
scans were performed by one of three nurses trained in its use and with experience of 
conducting more than 50 scans. Those with indications of liver disease on the biomarker 
(n=442) were then offered a FibroScan®. Results demonstrated the inadequacy of screening 
using routine LFTs alone, with 26.8% (98/366) of those participants who required and attended 
for a FibroScan® eliciting an elevated result of ≥8kPa despite 72% (71/98) of these participants, 
having normal LFTs. In addition, 11 patients were identified with definite cirrhosis, which had 
not been previously diagnosed. By conducting this research in the least deprived area of 
Nottingham, it is possible that those taking part were less susceptible to the co-morbidities and 
lifestyle factors affecting those from a more deprived group. Harmen et al (2015) acknowledge 
that their findings need to be tested in other populations, to check the validity and 
generalisability of their claims. Of interest to this cirrhosis screening study is the uptake of 
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FibroScan® in this population, out of the 442 participants recommended to attend for a 
FibroScan®, following the result of their blood biomarker, a total of 77 (17.4%) either refused a 
scan or did not attend; an uptake of 82.6%. This suggests that FibroScan® is acceptable in this 
population and supports the claims to acceptability seen in the cohort of PWIDs in the studies 
by Marshall et al (2015) and Foucher et al (2009) discussed previously.  
Roulot et al (2010) carried out a prospective observational study to evaluate the use of a 
portable FibroScan® device as a screening tool within the general population by offering 
screening to all patients over the age of 45 years old attending a social medical centre in a 
deprived area of France for a routine medical review. In addition to the FibroScan®, conducted 
by one physician, with experience of over 500 scans, participants were offered a clinical 
examination and laboratory blood tests in order that FibroScan® results were more likely to be 
valid, according to the study by Castera et al (2010). No data are offered to show how many 
potential participants declined to take part in the study, so no comment can be offered as to its 
perceived acceptability to those offered the intervention. The prevalence of an elevated LSM, 
with a lower threshold of >8kPa, and concordant with that used by Harmen et al (2015), was 
7.5% (89/1190) in this large invited sample (n=1190) over a recruitment period of two and a 
half years. Participants with a LSM of >13kPa were offered a liver biopsy, as were those with a 
LSM >8kPa and clinical indication of liver disease. In all participants with histologically 
confirmed cirrhosis, each had an obvious risk factor such as drinking to harmful levels, obesity 
or viral hepatitis. Roulot et al (2010) state that among the five patients with alcoholic liver 
disease three had stopped drinking completely; it is not, however, stated over what period this 
was assessed and whether this was self-reported or assessed independently. Again, this study 
highlights the poor reliability of routine LFTs with 38/89 (43%) of those with LSM>8kPa having 
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normal ALT and GGT; as supported by the findings of Harmen el al (2015). While Roulot et al 
(2010) aimed to target the general population, they acknowledge that, by enrolling those over 
the age of 45yrs, they have targeted an older population, with a higher risk of liver disease and 
therefore cannot assume their results are generalisable. In addition, while this study was 
undertaken in a deprived area of France those who took part may be more likely to have co-
morbidities which are less likely to be seen in a more affluent area. As with Harmen et al (2015) 
the study results would be more representative of the general population if they had been 
carried out across several sites, within differing areas of deprivation. 
In their prospective observational intervention, described as a “pilot feasibility study” Fabrellas 
et al (2013) sought to determine the feasibility of a nurse led screening service for CLD using a 
FibroScan® device in a primary care nurse consultancy in Spain. The research team randomly 
chose participants from the health registry and invited to participate by telephone. Fabrellas et 
al (2013) did not state how many potential participants declined entry into the study, nor how 
the sample size was determined, other than stating how many participants agreed to take part 
(n=502). Two nurses trained in the use of the FibroScan®, with experience of 250 examinations 
prior to the study consulted with participants in a clinic specifically set up for the study. They 
collected participant demographics, blood samples to check for AST, ALT, glucose, lipids and 
viral hepatitis then conducted the FibroScan® with a lower cut off threshold of 6.8kPa. In a 
large sample of participants with reliable results (n=495/502) they uncovered a prevalence, 
within this cohort, of 5.7% (n=28) with elevated liver stiffness, suggestive of fibrosis. Without 
knowing the reasons for non-participation in those who were invited to take part in the study, 
it is difficult to comment on the generalisability of these results. Whilst the sample size was 
large it is possible that this type of intervention attracted those participants who already, 
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because of lifestyle factors, had concerns regarding their liver health; possibly eliciting a cohort 
with higher likelihood of CLD. However, these results are in line with the lower prevalence in 
Roulot et al’s (2010) general population study of 7.5%, as opposed to 26.8% in Harmen et al 
(2015) who directly targeted those at high risk. However, these studies cannot be directly 
compared as the lower threshold differs between 6.8kPa (Fabrellas et al 2013) and 8kPa 
(Roulot et al 2010 and Harmen et al 2015). Further stratification would be useful in determining 
the optimum lower threshold i.e. how many participants with a FibroScan® result between 
6.8kPa and 8kPa in the Fabrellas et al (2013) study had subsequently been diagnosed with 
significant fibrosis. 
Fabrellas et al (2013) state they targeted the general population; with no comment as to 
whether the nurse consultancy used was in an area of low or higher deprivation or mixed. Of 
the participants in whom successful readings were obtained, 441/495 (89.1%) were described 
as Caucasian; this differs from Roulot et al (2010) who held their study, also targeting the 
general population, in an area of deprivation, with a high percentage of immigrants; the 
percentage unreported. Again, this causes difficulty in directly comparing both studies. 
However, regardless of this, neither yielded as high a level of elevated LSM as that in the study 
by Harmen et al (2015.)  By directly targeting those at high risk, albeit in an area of low 
deprivation, Harmen el al (2015) yielded 26.8% of participants with an elevated LSM.  Roulot et 
al (2010) yielded 7.5% through offering screening to those in the general population over the 
age of 45yrs; with those subsequently diagnosed with cirrhosis having known and identifiable 
risk factors for CLD. In view of resource restrictions, for reasons of efficiency, it would seem 
preferable to target a population at high risk; as is the case in this study. 
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While Harmen et al (2015) devised a novel algorithm for highlighting those requiring further 
investigation of liver disease, the initial test was blood based; despite the availability and 
subsequent use of the FibroScan® device. Roulot et al (2010) also undertook blood samples at 
the same time as the FibroScan® while they demonstrated that the FibroScan® was valid as the 
initial screening tool for liver disease. In their study, Fabrellas et al (2013) blood sample were 
taken during the consultation, but it is unclear who interpreted these; the author does state 
that they had a close link and effective communication with the local liver specialist unit. It is 
possible that interpretation of the bloods may have been carried out by staff there, but this 
cannot be assumed. The invasive nature of blood tests, the subsequent need for interpretation 
of a range of serum markers and the high volume of data this would produce per participant, 
has influenced the decision to use the FibroScan® device as the sole instrument for screening in 
the nurse led innovation; the subject of this thesis. 
While Fabrellas et al (2103) claim that it is feasible for nurses to carry out screening for CLD, 
using FibroScan®, in the general population it is not clear how much of the intervention was 
nurse led, beyond carrying out the FibroScan® and interpretation of the result. Nursing input to 
the design of and development of the intervention can be assumed, as four of the nine authors 
are qualified nurses and the article was published in “Nursing Research”. While the nurse led 
aspect of this study is of interest to this current study, it was conducted in a non- UK primary 
care setting; therefore, it cannot be assumed that the cohort is directly comparable to this 
study targeting service users attending an alcohol support centre in Edinburgh. In addition, the 
participants were randomly selected, rather than targeted according to behaviour predisposing 
them to liver disease; giving a different emphasis to their study aims and outcomes than is the 
case in this study. 
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1.05 Conclusion of Review 
The limited literature focusing on community screening with a FibroScan® device in alcohol 
services suggests that research in this area is long overdue. While the studies reviewed suggest 
acceptability of FibroScan®, critical review of the evidence revealed potential biases in 
recruitment, study design limitations, the possible influence of the motivation of those 
recruiting on the motivation of those taking part and the provision of a financial incentive on 
the success of their recruitment strategies. This, therefore, influenced the choice of 
recruitment strategy in this study; where the researcher was not actively involved in 
recruitment of potential participants. Reviewing the literature highlighted the inadequacy of 
serum markers in screening for liver disease and the higher prevalence of disease outwith the 
acute setting. It also highlighted that targeting a high-risk group is more efficient; an important 
consideration for cost effectiveness, which influenced this study design. Finally, while one study 
suggests that a nurse led screening service with a FibroScan® device is feasible (Fabrellas et al 
2013), this was conducted in a non-UK primary care setting and is unlikely to be directly 
comparable with the community alcohol setting in this study in terms of service management 
and cohort demographic.  
The key themes emerging from this critical review of the literature, therefore, indicate that 
FibroScan® is an acceptable intervention in community settings, with the targeting of high-risk 
groups being more effective than recruiting from the general population. The inadequacy of 
blood tests alone, in screening for liver disease, has been highlighted and the increased 
incidence of CLD in regional clinics suggests a need to target groups not currently accessing 
mainstream care. Finally, there is little evidence of studies, to date, being nurse-led in their 
design and development. 
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This chapter outlined the current climate in liver disease. Through identifying a gap in provision 
of service in the potential early identification of CLD, the author promotes the argument that 
early intervention can be achieved by taking screening into a community alcohol service, to 
those defined as being at high risk of liver disease, with the use of a portable FibroScan® 
device. The methodology and study design shall be outlined and evaluated in the following 
chapter. 
1.06 Update of Literature Search and Review 
Through an update of the literature search on completion of data collection, further articles on 
studies were found which offered FibroScan® intervention in non-acute settings. While, at this 
stage, these studies could not influence the development of this screening study they are of 
interest when considering its overall outcome.  These included a study by Arain et al (2016) 
who conducted a randomised controlled trial looking at health knowledge and uptake of 
screening and treatment for hepatitis C in a small cohort (n=25) of PWID in a community 
setting receiving health promotion and a FibroScan® compared to a small cohort (n=27) who 
did not receive this intervention and were considered “standard of care”. This study was not 
chosen for further critique due to the small sample size, making it difficult to generalise the 
results (Creswell 2014) and, more importantly for this screening study, the FibroScan® was not 
carried out in the community; with participants being taken to acute services in a taxi to have 
this carried out. This required the taxis to be pre-booked, once numbers were confirmed in 
advance, standing in contrast to the drop-in method of recruitment and the overall design of 
this screening study. Cheng et al (2016) conducted a general population study which excluded 
those drinking to harmful levels. Cheng et al (2018) utilised a FibroScan® device in a community 
setting, its focus was on surveillance in a cohort with known CLD; rather than screening to 
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uncover new disease or testing its acceptability in this setting. Solomon et al (2016) conducted 
a prevalence study for liver disease in a community of PWID in India. Their incidence of disease 
is difficult to compare with the screening study as this was a drug using cohort as opposed to a 
group drinking to harmful levels. In addition, while their recruitment centre was situated in the 
community it was conducted in a “Centre for Substance Abuse Research” suggesting this facility 
may not be comparable to the drug and alcohol support centre chosen as the research venue 
for this study.  
Bloom et al (2018) conducted a prospective observational study recruiting patients with 
hepatitis C from 21 primary care practices in Victoria, Australia with a hospital cohort being 
recruited for comparison. The aim of this study was to assess the prevalence of elevated LSM in 
patients being managed in the community and to evaluate predictors of advanced liver disease, 
comparing this with the hospital cohort. Participants were followed up longitudinally, with a 
median follow up of 15.2 months and monitored for liver-related events. Participants were 
invited to attend, differing from the recruitment strategy in this screening study with a 
convenience sample of participants. In addition, they were not screening for CLD, as this group 
were already known to have hepatitis C. However, of interest to the screening study is the 
uptake of the FibroScan® intervention and engagement in specialist follow up of those who 
required onward referral, with a lower FibroScan® threshold of 8kPa in this large sample size 
(n=1134). Uptake of screening was 76% (859/1134) in the community cohort with 55% 
(128/233) engagement in specialist services for those requiring onward referral. Without a 
qualitative element to their study (Bloom et al 2018) it is not known why the uptake they found 
was so high and, with a cohort already known to have CLD, it is possible that concern regarding 
their known disease could have been a factor. Incidence of raised LSM in this study is not 
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directly comparable to the screening study, as this cohort are known to have CLD; indeed, that 
is an inclusion criteria. The screening study targeted a cohort at high risk of CLD. While the 
uptake and engagement will be further discussed in relation to the screening study, later in this 
thesis, the incidence of CLD in the community cohort, which was significant and comparable to 
the hospital cohort, will not. This was not a nurse-led intervention, with one of two 
Hepatologists carrying out the assessments, including the FibroScan® Bloom et al (2018); the 
possible relevance of this will be discussed later in the thesis.  
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Chapter 2: Methods 
2.01 Introduction 
This chapter will present and justify the research question, aim, hypothesis and study 
objectives. In addition, the theoretical perspectives and methodology underpinning the study 
design are discussed and analysed. Thereafter, this is followed by a critique of the development 
of the data collection tool. To achieve the aims of this study in recording the uptake of the 
FibroScan®, determining the prevalence of undiagnosed CLD and reporting attendance with 
specialist liver services within, and at, six months post intervention a prospective quantitative 
observational design was developed. Analysis of data sought to determine associations 
between variables such as FibroScan® result and length of drinking, quantity of alcohol 
consumed weekly and BMI; consistent with the philosophical underpinnings of a positivist 
paradigm (Rolfe 2013).  
2.02 Research Question, Aim, Hypothesis and Study Objectives 
The aim of this study was to determine the viability of a service providing screening for liver 
disease, with a portable FibroScan® device, to a group concerned about the health of their liver 
due to elevated levels of alcohol consumption. The research question “Can a portable 
FibroScan® device be an acceptable tool for cirrhosis screening in a community alcohol support 
service?” was posed with a hypothesis that the FibroScan® device would be an acceptable tool 
for cirrhosis screening in this setting. This prospective observational study, which will be 
discussed in this chapter, enabled the following objectives to be completed: 
1. Record the uptake of a FibroScan® in individuals accessing one community alcohol 
support service. 
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2. Determine the prevalence of undiagnosed significant liver disease in a self-selected, 
convenience sample of individuals accessing one community alcohol support service 
3. Report attendance at six months following referral to specialist liver services, of those 
participants referred with a FibroScan® reading ≥ 7.1kPa. 
2.03 Theoretical Perspective and Methodology Underpinning the Study 
This study proposed the use of the portable FibroScan® device for the use of early detection of 
liver disease where, whilst it is a validated tool (Nguyen-Khac et al 2008, Thiele et al 2015), 
higher quality diagnostics are available. However, these tools, such as MRI are unsuitable for 
use in the community setting due to their lack of portability or requirement for a specially 
trained operator. Maier’s Law states that E=QxA (Sermeus 2015) with E=Effectiveness, 
Q=Quality and A= Acceptability. This demonstrates that the effectiveness of an intervention of 
the highest quality will be poor if it has poor acceptability; while a suboptimal intervention with 
good acceptability will be more effective (Sermeus 2015). This translates well to this study, 
where uptake of screening may indicate a level of acceptability (Sekhon, Cartwright and Francis 
2017) and may, subsequently, be effective for screening in this community alcohol support 
setting.   
A Nurse Led Cirrhosis Screening service using a portable FibroScan® device in an alcohol service 
requires several components to be in place. Each component contributes to the success or 
otherwise of the intervention and can be presumed to include the FibroScan® device, a nurse 
qualified in its use with experience and motivation to work with “hard to engage” groups, 
written participant information, a clear, safe, participant pathway for those requiring onward 
referral, participant motivation to learn of and improve their liver health and suitable premises 
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within an alcohol service to conduct the study. In this respect, this resembles a multi-
component complex intervention and, as such, theoretical underpinning and guidance in its 
development and implementation has been sought using guidelines on developing and 
evaluating complex interventions compiled by the Medical Research Council (MRC 2008). 
Possible facilitators and barriers to the success or otherwise of the intervention were explored, 
in addition to practical effectiveness and whether this intervention could operate within the 
setting of an alcohol recovery service (MRC 2008). 
In preparing for implementation of the study it was important to consider possible facilitators 
and barriers (Dogherty and Estabrooks 2015). Self-efficacy, the confidence in one’s own ability 
to exert control over their behaviour, is an important consideration in predicting positive 
health behaviour (Bandura 1997) and can be influenced by environmental, personal and 
behavioural factors (Brannon, Feist and Updegraff 2014).  Factors which can enhance self-
efficacy, include verbal support, in the form of counselling and vicariously experiencing others 
health benefits from health behaviour change (Brannon, Feist and Updegraff 2014). These 
enhancing factors are available in the form of one to one and group support at the recovery 
centre chosen as the research venue. According to the Health Belief Model (Sharma 2011), 
factors which influence health behaviour include perceived susceptibility to disease, perceived 
severity of disease, perceived benefits of health enhancing behaviour and perceived barriers to 
health enhancing behaviour. The Theory of Planned Behaviour states intention is the best 
predictor of behaviour change, in addition to self-efficacy and external control factors i.e. 
barriers or facilitators to change (Marks et al 2015).  
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While most components of this cirrhosis screening intervention are provided through external 
factors such as the FibroScan® device and nurse time, an assumption is made that potential 
participants are demonstrating a degree of self-efficacy through their attendance for support 
with recovery from alcohol. Similarly, it is assumed that, should they participate in cirrhosis 
screening, they are, at the time of participation, demonstrating ‘self-efficacy’ according to 
Bandura (1997), perceived susceptibility to disease and intention to change their health 
behaviour (Marks et al 2015, Sharma 2011). It is important to consider self-efficacy, in the 
context of the Health Belief Model and the Theory of Planned Behaviour, as one of the integral 
components to this intervention as it may prove to be a key factor in both recruitment and 
retention to the project; ultimately leading to its success or failure. 
Another consideration is practical effectiveness and the attitude towards the study of the 
multiple agency staff, acting as study hosts, within the chosen venue (MRC 2008). For example, 
the only room suitable for carrying out a FibroScan® is the largest in the building and that used 
for group activities; giving some concern for the potential for conflict as the study progressed. 
Practical effectiveness, whether the intervention will work in everyday practice, is a key 
question to consider in evaluating a complex intervention (MRC 2008) therefore designing the 
study to be as low maintenance for venue staff, as possible, was considered to be important in 
developing a sustainable service which would continue beyond the research phase and could, 
possibly, be integrated into routine services offered there. Venue staff were therefore 
consulted and involved in the design of the study from an early stage. This is also consistent 
with the key outcomes of Normalisation Process Theory where normalisation is the willingness 
to integrate a new intervention into everyday practice (May 2015). Normalisation Process 
Theory seeks to guide process development through considering such factors as coherence, 
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cognitive participation, collective action and reflexive monitoring (Murray et al 2010). To have 
coherence it is important that the intervention is easy to describe, and that hosting staff are 
aware of its purpose. It is also important to convey how this differs from current practice (May 
et al 2009). Cognitive participation, where staff engage and participate with their role, requires 
commitment and engagement with the intervention which is easier to achieve if staff think it is 
a good idea (May, Sibley and Hunt 2014). Collective action, where staff engage with the 
intervention as a group (May, Sibley and Hunt 2014) requires some thought as to how the 
intervention will impact on the current workload of staff hosting the study, while reflexive 
monitoring seeks to establish if staff feel there has been benefit to both them and their 
patients in hosting and possibly recommending the intervention (Murray et al 2010). 
Normalisation Process Theory focusses on what people do and takes account of the turbulence 
and uncertainty often associated with the introduction and embedding of an innovation into an 
existing service (May 2013). This is an important consideration in the introduction of screening 
for liver disease in this venue; especially as the author was a visiting professional to this setting, 
was not a permanent member of staff and had no managerial responsibility for any of the local 
staff. 
2.04 Developing the Screening Intervention 
When investigating the possibility of delivering a screening service to a community alcohol 
service there was no capacity within the author’s clinical role to offer this within her work 
schedule. In addition to this, the liver unit did not own, or have access to, a portable FibroScan® 
device. Amongst some of the more senior staff members in the unit and with some members of 
the author’s team there was a general resistance to taking this innovation forward. Concerns 
were expressed regarding a possible breach of the currently defined role of the Hepatology 
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nurse and anxieties regarding the future of this role should this study go ahead. This desire to 
maintain the status quo is consistent with some of the common sources of resistance to change 
by current staff, often found in taking new projects forward (Dwyer, Stanton and Thiessen 
2004). In addition, the capacity of the unit to deal with a source of referral from the community 
in addition to referrals from GPs was a source of anxiety; with one senior member of the team 
describing the innovation as “looking for work”. Within this climate of resistance, there was 
initial support from a senior member of the medical team in addition to management within 
the community alcohol service identified as the possible research venue.  
In order to drive this innovation forward, the author worked autonomously to cement this 
support from her senior medical colleague, through advanced level discussion, influencing, 
leadership and negotiation skills (Stasa et al 2014); skills defined as a hallmark of advanced 
clinical practice by NHS Scotland (2017) and NHS Health Education England (HEE 2019). From 
the outset, the author organised meetings with her management within the NHS. In time, this 
resulted in developing support from key members of the NHS management team with the 
author finally being able to influence a positive outcome to enable the study to go ahead. 
Through this negotiation with senior management, she was able to secure time within her work 
schedule to deliver the intervention. This was set at two sessions per week for the duration of 
the data collection period; at that time undefined.  
A pragmatic stance was taken with this study, in order that it can go ahead, rather than waiting 
for conditions to be optimal to do so (Creswell 2014). In considering time resource as part of 
the “budget” for managing this as a project with defined resources and outcomes (Dwyer, 
Stanton and Thiessen 2004) this allocated time set the frequency of the research clinics to two 
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sessions per week; with an agreement that admin time would be within the author’s own time. 
Subsequently, negotiation between management of a local alcohol recovery centre and the 
author, who currently delivered a clinic offering hepatitis C treatment once weekly there, were 
successful in securing a suitable room for two sessions a week, for the duration of the study; at 
that point undetermined. 
While developing the study the NHS Innovation board called for applications from NHS staff to 
pitch for funds to support healthcare innovations. Funding ideas were reviewed by the board 
for selection to attend an NHS Lothian Innovation event. At this event the idea could be pitched 
to senior NHS, Scottish Government and Private Industry executives; a role requiring advanced 
level negotiation and influencing skills (NHS Leadership Academy 2013). Initially, the funds for 
the portable scanner, at approximately £45,000 to purchase, were deemed too high for this 
funding stream. However, the board were sufficiently persuaded with the idea and invited the 
author to apply to pitch for funding to rent the device for a period of six months at a more 
modest cost of £6020. This, amended, application was subsequently accepted, and she was 
invited to pitch the idea for two minutes, using one power point slide to an audience of just 
over one hundred, consisting of NHS executives, Scottish Government representatives and 
private sector entrepreneurs. Once all 30 candidates had pitched, the audience voted, using an 
electronic voting system, against the following criteria: “This proposal is an innovative 
approach for NHS Lothian which supports the delivery of safer, more effective and patient 
centred services”. Only the first five pitches with the most votes were allocated funding.  The 
result of the voting showed that 48% of the audience strongly agreed with this statement, 35% 
agreed, 13% neither agreed or disagreed, 3% disagreed and 1% strongly disagreed (Appendix 
3). The subsequent decision from the Innovation Board was to provide the funding for rental of 
31 
 
the device for six months. This, therefore determined this should be a time limited study with a 
data collection period to six months, rather than being set by other scientific criteria such as 
optimal sample size.  
At this time, NHS Lothian Research Futures invited nursing, midwifery and allied health 
professional staff to apply for funding and support in doctoral study. The author presented her 
proposal to the panel for selection and was subsequently successful in securing funding and 
study time for five years to take this innovation forward as the subject of this professional 
doctorate; assisting in validation of the innovation as conforming to NHS Lothian’s priorities for 
service and nursing research and development. Negotiation and leadership qualities were also 
demonstrated through securing the further resources required; such as time to develop and 
carry out the research within work time and provision of the room within the chosen research 
venue. This also demonstrates the skills of the author in her ability to influence a range of 
audiences with varying agendas and consistent with the high level of autonomy, leadership, 
complex decision making in creating and developing an innovative solution with the aim of 
enhancing patient outcomes as defined by advancing clinical practice (HEE 2019, NHS Scotland 
2017). 
However, in the course of developing this innovation, not all negotiation elicited a positive 
outcome. As previously mentioned, there was initial resistance to its progress from some 
members of the author’s nursing team and the wider medical team, within the liver specialty. 
Whilst challenging for the author, this resistance is common in any prospective service 
development or potential role expansion (Dwyer, Stanton and Thiessen 2004). With this 
progress, it was important for the author to understand the rationale behind the perceived 
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resistance from the wider senior medical team and some nursing colleagues. In particular, the 
author felt it was important to understand the resistance from her nursing colleagues, leading 
to a series of meetings focusing on resolution of this. In leading on this innovation and to 
ensure transparency, as far as possible (Reed 2018), she presented her proposal at one of the 
liver unit’s weekly educational meetings. However, the timing of this presentation was carefully 
arranged to be in advance of data collection but after management, ethics approval and 
funding had been granted. In advancing this nurse led initiative, it was important to exercise 
and display autonomy (HEE 2019). With the relevant approvals now in place, the author was 
not asking permission to take this innovation forward but providing the opportunity to listen to 
any possible concerns or suggestions staff may have and provide answers and reassurance 
where possible; ultimately, to ensure the wider team felt they had the opportunity to feel fully 
informed. In identifying a need for this study and pursuing funding for the FibroScan® device the 
author became the Principal Investigator within the research team. This presented a challenge 
to her leadership skills as each member of the research team were more senior in their 
professional role than her and it has been necessary for her to take decisions on aspects of the 
research study where there had been a difference of opinion. This is consistent with skills 
required in project management, where an individual can be responsible for a defined piece of 
work while being junior in professional status to others in the wider team (Dwyer, Stanton and 
Thiessen 2004). This enabled the author to further develop her leadership skills and required 
complex analytical, negotiation and decision-making. These skills shall be further explored in 
Chapter 4: Discussion.  
This chapter introduces the rationale for a study screening for liver disease in a community 
alcohol support setting with a FibroScan® device; working collaboratively with staff in this area. 
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Through specialist knowledge of liver disease, evaluation of current policy in the area of liver 
disease and public health and critique of the literature the author presents the case for 
initiating and taking this study forward. The challenges and the advanced clinical practice skills 
required in doing so, within her current role as a Hepatology Nurse Practitioner, are evaluated 
and will be revisited during in Chapter 4: Discussion. The remainder of this chapter shall outline 
the study design, methods and underpinning theoretical framework for this study. 
2.05 Developing the Data Collection Tool for Assessment of Participants  
Screening for cirrhosis with a portable FibroScan® device in alcohol services is not currently 
offered as a service at local level; nor were there published data in this field to suggest that this 
was currently operational within the UK. For this reason, no validated assessment or data 
collection tool was available specifically for use in this context.  This section of the chapter 
explores the development of the structured data collection tool devised to support the 
FibroScan® test and ensure focused patient assessment, through adapting systematic 
assessment (Snadden et al 2013). Its purpose and factors ensuring content validity shall be 
explored and evaluated. 
In construction of the data collection tool three key objectives were considered. Firstly, it 
should enable a lifestyle risk assessment for liver disease to establish if participants fit the 
inclusion criteria of those who are worried about the effects of their drinking on the health of 
their liver. In this respect, it should facilitate appropriate signposting to other support services 
where necessary and enable tailored health promotion advice. Secondly, it should facilitate a 
medical and family history for participants in order that factors increasing their risk of CLD can 
be documented and further assessment offered where appropriate (Snadden et al 2013). 
Finally, it should describe the sample population in such a way that data can be transferred to 
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the Statistical Package for Social Sciences (SPSS) for analysis (Lobiondo Wood and Haber 2014). 
Prior to use in the study the data collection tool, content validity was checked by one clinical 
(Consultant Hepatologist) expert, and one academic expert (Senior lecturer and author) before 
being finalised. 
As potential participants to this study could drop in to the bi-weekly research clinic; having 
requested a participant information sheet from the research venue reception, and with the 
information on exclusion and inclusion criteria offered in the research pack, self-screening for 
suitability to the study was expected. Further assessment regarding suitability by the author 
took place through discussion with potential participants in gaining their consent and before 
proceeding to data collection; therefore, screening for inclusion to the study was not a 
requirement for this tool.  
Lifestyle risk for CLD alone could result in missing other key causes of liver disease and, in the 
event of a participant displaying signs or symptoms of liver disease, onward referral to 
specialist services would be organised; regardless of the FibroScan® result. Including a health 
assessment to complement the lifestyle risk assessment assumes a degree of reliance on the 
knowledge and skills of the author, working at an advanced level of practice (Kenney 2009) in 
their use of systematic enquiry to pursue a specific line of questioning in response to answers 
suggesting possible liver disease (Snadden et al 2013). This, in turn, could conflict with the aim 
of homogenicity in reporting of data where closed, dichotomous questions should be used 
(Moule and Goodman 2013). Incorporating questions which aid systematic enquiry, therefore, 
has the potential to result in a range of unnecessary data which are cumbersome to analyse 
and may bring disproportionate attention to signs and symptoms in a study taking place in a 
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non-medical setting. This, in a medical condition where the absence of these may be assumed 
in most participants (Williams et al 2014).  In addition, consideration was given to time 
constraints for the study. With thirty minutes allocated to each participant, there was a limit to 
the extent further questioning could be incorporated into the consultation, as it risked 
overburdening the participants who, should they be identified as having a risk of CLD through 
either the FibroScan® result, or their history, would be referred for a comprehensive medical 
assessment with a senior member of the medical team in Hepatology. It was therefore decided 
that, while a health assessment was an important element of the data collection tool, scope 
and requirement for full systematic enquiry would be limited. Focused, problem orientated 
enquiry (McGee 2003) was expected in this study and was within the author’s advanced scope 
of practice (NMC 2015). The outcome of any further questioning would be documented and 
reported in a dichotomous way with some provision for free text reporting within an excel 
spreadsheet to enable further understanding of the possible signs or symptoms found in any 
sample requiring onward referral. Following completion of the excel spreadsheet data would 
be transferred to the codebook, developed for this study to be compatible with SPSS (Appendix 
4). 
In developing their tool for the collection of human responses of outpatients with chronic 
cardiovascular diseases, Carneiro et al (2014) devised a ninety-question nursing assessment 
tool for data collection. This was largely based on the North American Nursing Diagnosis 
Association (NANDA) taxonomy of nursing diagnostic terminology and Gordon’s Functional 
Health Pattern, which organises data into domains for structure and clarity (Gordon 1994). 
Their resulting tool consisted of four sections, which included demographic information, clinical 
data, physical examination and interview/subjective data. Carneiro et al (2014) suggested this 
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tool could be adapted for use with other chronic illnesses. However, they also state that this 
tool took an hour of nurse time to complete; this was considered in breach of the aim to avoid 
overburdening the participants and therefore prohibited its consideration for use, in its 
entirety, for adaptation in this study. In addition, as the NANDA taxonomy, which is not widely 
used in the UK, was an underpinning element to this tool concerns were raised as to the 
transferability of it psychometric properties for use in the UK.  
Rather than being guided by specific questions, therefore, a more global approach was taken, 
and development of the data collection tool was, in part, guided by the four domains of the 
tool developed by Carneiro et al (2014) i.e. Identification, Clinical Data, Physical Exam and 
Interview. Their largely quantitative interview/subjective section was justified in the context of 
their study looking at the human responses of patients as it ranged from perceptions of health 
to nutrition, elimination, spirituality and self-perception in line with Gordon’s Functional Health 
Pattern taxonomy (Gordon 1994). This could be less justified in a study aiming to screen for 
liver disease within a consultation lasting around thirty minutes (Moule and Goodman 2013). 
However, in taking a pragmatic approach a more focused, problem based (McGee 2003) 
strategy to data collection, within the time constraints of the consultation, was considered 
important in identifying participants who may be identified with an elevated risk of CLD, 
regardless of FibroScan® result. Provision for subjective reporting by the participant was 
considered important in cases where they may wish to self-report details which may be 
pertinent but not specifically asked during the consultation. For this reason, a short “other” 
section was included to enable this.   
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Carneiro et al (2014) included a section to document physical examination. While, in this study, 
no full physical examination would be offered participants were asked whether they are aware 
of possible signs and symptoms of chronic liver disease. Indeed, the response to this may have 
elicited further focused systematic enquiry by the author (Snadden et al 2013) and onward 
referral to specialist services, regardless of the FibroScan® result and, in those with raised 
results, provide further support to their diagnosis.  It was therefore considered important to 
have, albeit, a short section for this. 
2.06 Alcohol History 
According to Sargent (2009) a comprehensive alcohol history should include quantity, strength 
of alcohol and pattern of drinking. Other relevant factors include age, when they started 
drinking alcohol, timing of last drink and whether they have any alcohol related offences. 
Validated screening tools for alcohol misuse include the FAST score and AUDIT C (PHE 2017) 
and are commonly used in health care settings for identifying those who are drinking to 
hazardous, harmful or dependent levels (Scottish Government 2012). This study was targeting a 
self-selected group who, through drinking to hazardous, harmful or dependent levels, were at 
elevated risk of liver disease and therefore the issue of whether the participant was drinking to 
levels, which concern them, is suggested by their attendance for support in alcohol reduction at 
the recovery centre and subsequent enrolment in the study. In this respect, questioning on 
alcohol related offences and timing of last drink may not be so relevant and there would seem 
no need to use either the FAST or AUDIT screening tool but to focus the history on questioning 
regarding behaviour, which may give an indication of liver disease risk.  Recording alcohol 
intake in units per week, length of drinking and pattern of drinking may be helpful in 
determining the level of anticipated harm to the participant’s liver (Williams et al 2014). 
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Recording whether a participant has a family history of alcohol misuse is important as this can 
indicate a possible predisposing genetic link to liver disease (Sargent 2009).  
A level of motivation in reducing alcohol intake was assumed in this cohort, due to their 
attendance at the community alcohol support service. Some participants may have previous 
attempts at detoxification from alcohol. In data collection this may be of interest as a possible 
reflection on their ability, in the past, to keep their resolve and may give an indication of 
possible areas for discussion in pitching a health promotion message in a motivational way 
(Sharma 2011) 
2.07 Body Mass Index (BMI), Metabolic Syndrome and Diabetes 
According to WHO (2019), a body mass index (BMI) of ≥ 30kg/m2 is an indicator of obesity. Non 
alcoholic fatty liver disease (NAFLD) occurs when fatty infiltration of liver cells results in 
damage of liver tissue (Sargent 2009). NAFLD can be present with or without inflammation 
(non alcoholic steatohepatitis or NASH) (Pinzani, Rosselli and Zuckermann 2011) and it is 
estimated that, due to either NAFLD or NASH, 15-20% of those who are obese will develop 
fibrosis or cirrhosis (ScotPHO 2017).  The portable FibroScan® device used in the study could not 
support an XL probe, resulting in an increased likelihood that results in patients with a BMI 
≥30kg/m2 were unreliable with the medium probe (de Ledinghen 2012). Thus, from a health 
promotion aspect recording weight and height to establish a participant’s BMI can enable a 
discussion regarding the liver health implications of a raised BMI. From a data collection point 
of view, in addition to aid description of the study population, recording BMI can give insight 
into the reason why some scans may be unreliable. In individuals who are not currently obese a 
history of obesity can be a significant factor in liver disease (Muir 2015), as his may already 
have resulted in cirrhosis; this was also be included in the assessment. 
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Metabolic syndrome, the features of which include obesity, hyperlipidaemia and insulin 
resistance is (Sargent 2009) linked to NASH and the development of cirrhosis (Muir 2015). Type 
2 diabetes is increasing rapidly in Scotland with 276,430 cases at the end of 2013; giving a 
prevalence of 5.2% (ScotPHO 2017). This can also be a clinical feature of cirrhosis due to 
disturbed glucose use or decreased removal of insulin by the liver (Shuppan 2008). Type 1 
diabetes can be linked to development of cirrhosis (Harmen et al 2015) therefore it seemed 
prudent to make specific reference to diabetes when taking a medical history for this study. 
2.08 Blood Borne Viruses (BBVs) 
Approximately 50,000 of the Scottish population are infected with hepatitis C, with less than 
50% currently aware of their diagnosis (ScotPHO 2017).  While 5% of cases will self-clear, 5-15% 
of those with chronic infection likely to develop cirrhosis over 20 years if they remain untreated 
(ScotPHO 2017). Data linking the 10% of those with hepatitis B who develop chronic infection 
with CLD is currently unavailable (ScotPHO 2017) but those chronically infected with hepatitis B 
and C are at increased risk of developing cirrhosis (Muir 2015). While transmission of hepatitis 
B and C can occur through direct blood-to-blood and sexual contact, hepatitis B can also be 
contracted from close contact with infected body fluids (Sargent 2009). In establishing a 
participant’s risk of contracting viral hepatitis, it is important to consider lifestyle factors which 
increase the risk of BBVs such as injecting drug misuse and other drug taking risks, tattoos in 
unlicensed premises, travel to high prevalence areas and high-risk sexual practices or 
unprotected sex with an individual with a high risk of BBVs (Scottish Government 2015). Risks 
from exposure to blood products or unsterile surgical or injecting equipment in the UK prior to 
the development of an antibody test for hepatitis C in 1991 (ScotPHO 2017) or in areas outwith 
the UK where sterilisation procedures may be suboptimal carry a risk of BBVs and occupational 
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exposure, such as needlestick injury should be included in any BBV risk assessment (Scottish 
Government 2015). 
2.09 Other Factors with Possible Adverse Effects on Liver Health 
It is important to establish whether participants carry a possibility of a genetic liver disorder 
such as haemochromatosis or autoimmune hepatitis (Sargent 2009). This can be elicited 
through establishing whether there is a family history of these conditions as the participant is 
unlikely to have symptoms and, if not already diagnosed, unlikely to be aware of having these 
conditions themselves (Sargent 2009). However, as discussed elsewhere in this section, while 
an early iteration of the data collection tool (Appendix 5) included reference to autoimmune 
disorders on page one, it was suggested, through discussion with senior medical colleagues 
that this could be included in more general questioning regarding participant’s own and family 
history rather than a stand-alone question.  
Consideration should be given to medication, whether it is over the counter, prescribed, herbal 
or illicit drugs which may cause abnormal liver function tests and hepatotoxicity (Sargent 2009). 
This again will help to inform a diagnosis should the participant require onward referral. 
Smoking status should be recorded due to its ability to exacerbate existing liver disease 
(Schuppan 2008). A section for blood results was included in the early data collection tool. In 
further considering the participant pathway this was removed as only those requiring onward 
referral were required to have blood taken and, at this point, they were registered as NHS 
patients. 
As this study is targeting a hard to engage population (Brackertz 2007, Watt 2013) and, in view 
of evidence suggesting improved engagement when reminders are issued (Wong et al 2009) 
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participants requiring onward referral would be asked if they felt they would benefit from a 
text reminder before their appointment at the nurse led liver clinic. Their response would be 
documented in the data collection tool to ensure this was noted. 
2.10 Fasting Status and Demographics 
As discussed in the previous chapter, and in line with evidence to suggest that FibroScan® 
results are raised after eating (Lemoine et al 2014), it would seem prudent to document when 
the participant last ate and whether they have presented in a fasted state. In order to enable 
further contact with participants’ identifiable information can include their name, date of birth 
or community health index (CHI), address and contact telephone number. Provision was made 
by the author, therefore ensure these were locked in a drawer in the author’s office to ensure 
security of data; as required by the Ethics committee and recommended in Good Clinical 
Practice Guidelines (NHS Scotland 2014). GP details were recorded, in order that the GP can be 
informed of their participation in the study. To establish whether participants in the study were 
the target group of those who are accessing support in alcohol recovery, the agency or support 
group accessed by each participant was also documented. 
2.11 Structure of Consultation 
As with any consultation developing a good rapport is important and (Snadden et al 2013) and 
Fawcett and Rhynas (2012) suggest starting the consultation with less intrusive questions; an 
important consideration in devising the flow of questioning. While participants in this study 
were likely to accept the need for a thorough alcohol history, they may be less likely to expect 
to be asked questions regarding other potentially sensitive lifestyle factors such as high risk 
sexual activity and drug use. Douglas, Nicol and Robertson (2013) and Denvir (2012) suggest 
that the practitioner should brief the participant in advance that they will be asked certain 
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questions and the rationale given for the questions, in order that they are not seen as being 
disrespectful of the answers should they need to probe further and that the participant is not 
taken by surprise or offended by the questions asked. It would seem reasonable to commence 
with participant and GP details leading to which agencies, if any, the participant is linked in 
with at the recovery centre. While asking these questions the general demeanor of the 
participant can be assessed. Whether they seem anxious, intoxicated or, of relevance to this 
study, whether they seem to be centrally obese, to an extent which may make scanning 
difficult (Williams et al 2014), can be included in this initial assessment. Communication 
difficulties such as illiteracy, language difficulties or sight impairment may also be highlighted at 
this time and arrangements made to help with this if necessary.  
Following completion of the data collection tool and recording of BMI, participants were then 
asked to lie on a couch with their upper left quadrant exposed in order that the FibroScan® 
could be taken. As the FibroScan® gives an instant result; this was discussed with the participant 
at the time of screening and their follow up discussed. 
2.12 Research Data Collection 
The research clinic was carried out by the author, an appropriately trained and experienced 
Hepatology Nurse Practitioner. In keeping with the decision to utilise a recruitment strategy 
where potential participants would not feel coerced into taking part a decision was taken that 
the author would not approach them in the reception area of the research venue. Instead, this 
study was advertised on a rolling TV screen in the reception area, posters in reception 
(Appendix 6) and all consultation rooms. Potential participants could then volunteer. The image 
on this poster was chosen to demonstrate that participants are not required to undress, merely 
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that the upper left quadrant of the abdomen is exposed for access of the FibroScan® probe in 
the event of this assumption being a barrier to participation.  
Participant study information packs which included the participant information sheet and draft 
consent form, were numbered and available in the reception area. To assess uptake, the 
number of packs issued were counted against the number of participants in the study. While 
venue staff were not required to approach service users in the reception area to recruit to the 
study it is entirely possible that they drew attention to it and provided encouragement for their 
clients to take part. Indeed, this behaviour is more likely to occur if staff demonstrate a 
willingness to incorporate screening into their service and an ability to describe it; 
demonstrating coherence is an essential factor in the normalisation process (Murray et al 
2010). However, while this may conflict with their role in the study, as any member of staff may 
man the reception area at any time, it could also be argued that this was indicative of them 
engaging with the role of the receptionist in this study; demonstrating cognitive participation, 
another key factor in the normalisation process. A pragmatic approach needed to be taken as it 
was not possible for the author to monitor what level of engagement staff may take in the 
process of recruitment; as she was not sited there on a full-time basis. A need for practical 
utility was important in designing this study and it was considered important to build this in 
from an early stage (MRC 2008). Ultimately potential participants demonstrate tacit, or implied 
consent, by attending the research clinic where informed consent would be discussed with 
them (NHS Scotland 2014) prior to the intervention. While not the primary mode of 
recruitment, therefore, it was accepted that information giving and sign posting by staff could 
be accepted as part of the recruitment pathway for this study. 
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Venue staff checked that individuals taking a study information pack were given the 
opportunity to have the information read to them on the premises. If a participant wished to 
take part in the study, they could return to a research clinic at their convenience on a Tuesday 
or Thursday between 11-2pm. This would enable potential participants to attend on an empty 
stomach to enhance the quality of the scan (Lemoine et al 2014); a full stomach did not exclude 
participation in the study, as is current practice in the specialist liver service. Potential 
participants who were pregnant, had a pacemaker or known cirrhosis would be excluded from 
taking part in the study, according to guidelines in the use of the device (EASL-ALEH 2015). 
Following discussion of the purpose of the study written consent was taken to share 
information with the participant’s GP and other health professionals, as appropriate (Appendix 
7). In order to provide demographic data of the study cohort, to establish any possible link 
between FibroScan® result and BMI and to provide data, in the event of an unreliable 
FibroScan® result, participant’s height and weight were recorded, in order that their BMI could 
be established. A focused medical and lifestyle history (Snadden et al 2013) was taken, using 
the data collection tool specifically designed for this study (Appendix 8). The development of 
which was be discussed in the preceding section.  
2.13 Pathway Following FibroScan® 
Participants with a FibroScan® reading ≥ 7.1kPa were offered an appointment to attend a nurse 
led liver clinic within the service on another day, for further blood tests to determine the 
pathway of monitoring and follow-up. In the unlikely event of participants showing symptoms 
of CLD (Muir 2015), despite a reading ≤7kPa, an appointment for follow up would also be 
offered. The appointment date and time were given on the day of the FibroScan®. A reminder 
telephone call for the clinic appointment was also offered. 
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For those participants who showed no signs of cirrhosis from their scan (≤ 7kPa), lifestyle 
advice was reinforced through the literature offered at the research appointment (Drinkaware 
2013).  In the event of being unable to elicit a FibroScan® reading the GP was informed and 
invited to refer participants to the liver unit at the Royal Infirmary of Edinburgh (RIE) for further 
assessment, should they have any concerns regarding their liver health. Regardless of outcome 
all participants’ GPs were informed of their attendance and whether follow up was indicated or 
not. 
Referrals to specialist liver services and adherence to surveillance were reported through 
checking participants’ appointment details on Trak (online tracking system used by NHS Lothian 
for booking patient appointments and recording attendance) for the duration of the study. 
2.14 Sample, Sample Size, Data and Timescale 
The sample was a convenience sample in one community alcohol support setting in Edinburgh.  
This recovery centre has a catchment area which includes an area of deprivation in Edinburgh 
(SIMD 2017); therefore, those at most risk through their liver disease could be targeted 
(Williams et al 2014). 
Inclusion criteria included individuals over age 16, with the ability to provide informed consent 
who were attending either the triage facility for assessment of their support needs, or who 
were currently undergoing alcohol support in the centre. Exclusion criteria included the 
possibility of or known pregnancy, known to have a pacemaker, ascites, an open wound close 
to right 8th-10th intercostal margins, known cirrhosis and no alcohol history (EASL-ALEH 2015 
2015). 
As this study was evaluating the acceptability of the cirrhosis screening intervention in a 
community alcohol setting, no specific sample size was determined; with the sample size being 
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limited to the number of participants dropping in to the research clinics in a 24-week period. As 
this project planned to offer 12 screening slots weekly in a period of up to 24 weeks; a potential 
sample size of 288 participants was possible if all slots were utilised.  Data, therefore, was used 
to describe the population and variables for data analysis included FibroScan® result against 
age, gender, length of drinking and BMI. This data was coded using the codebook developed for 
this study and stored within the “Statistical Package for Social Sciences” (SPSS). Statistical tests 
included the “Mann Whitney U” for non-parametric data and the “Independent t test” for 
parametric data to analyse differences between groups (Pallant 2010). The development of this 
study spanned 12 months from inception through to securing funding, commencing data 
collection to completion of the data collection involved when monitoring engagement. This 
timeline and basic costings can be found in Appendix 9. 
2.15 Ethical Considerations 
This project targeted those attending a community alcohol support service who were 
concerned about the effects of alcohol on the health of their liver. As such, they can be 
considered a vulnerable group (Watt 2013). In working with a group who are drinking to 
harmful or dependent levels (Scottish Government 2012) participants may attend in an 
intoxicated state; thus, posing a challenge to the author in determining whether they were able 
to participate in the study. Informed consent, determined by establishing that participants are 
informed on the process and implications of the study, are competent to consent and are 
taking part on a voluntary basis was a vital element in recruitment (NHS Scotland 2014). While, 
through their attendance at the alcohol service, potential participants acknowledge they have 
concerns regarding their alcohol use it was important that anonymity was respected at all 
times and ensured any discussions regarding the study were carried out in private rather than 
47 
 
in the communal areas or in the immediate vicinity of the service; where other service users 
may overhear. 
During the screening consultation sensitive issues such as sexual activity, recreational drug use 
and public protection may be discussed. In addition to this, giving a potential diagnosis of 
cirrhosis can have life changing consequences. As a Hepatology Nurse Practitioner, the author 
has experience of asking such questions, referring to other agencies, as appropriate and 
supporting people with such a diagnosis. In the event of a public protection concern being 
highlighted, NHS Lothian Public Protection policy (NHS Scotland 2015) would be followed. 
Without robust data to determine the cost effectiveness for using a FibroScan® as a screening 
tool in the community (Stevenson et al 2012), delivering an intervention with the potential for 
earlier disease identification and reducing later presentation of disease which could improve 
the quality of life for those who manage to implement lifestyle changes and reduce the need 
for more expensive treatments, such as liver transplant, would seem ethically preferable to the 
status quo. 
To ensure beneficence when carrying out screening it is important to consider the possible 
anxiety a raised FibroScan® reading may cause to participants; in particular, when using the 
lower cut off value of 7.1kPa. It was therefore important to inform participants that a diagnosis 
could not be offered at point of screening and that elevated FibroScan® readings, which 
indicate possible fibrosis or cirrhosis would need to be confirmed with the range of tests 
available; such as serum biological markers and abdominal ultrasound, where appropriate. 
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In accordance with NRES guidelines (NHS Scotland 2014) it is the researcher’s duty to ensure 
security and confidentiality of any data collected during the research study. Raw data is 
required to be anonymised and held securely. In agreement with the ethics committee, data 
collected during this project was kept within a locked drawer in the author’s office at the RIE, 
within a lockable case when in transit or in a locked drawer within NHS offices at the research 
venue; if the author was not travelling directly back to the RIE. Only the research team (author, 
clinical collaborator and academic collaborator) have full access to this data. As this study 
involves NHS patients (NHS Scotland 2014) ethics approval had been sought and subsequently 
agreed by the South of Scotland Research Ethics Committee (Appendix 10).  
This chapter has explored the theoretical perspectives underpinning the development of the 
study design as it progressed from inception to completion. It highlights the project 
management, leadership and negotiating skills required by the author in bringing together the 
various elements required to ensure that the study ran to a high standard; in keeping with 
advanced practice. The following chapter shall illustrate and evaluate the results from this 
study; both demographic data, describing the participant population, the FibroScan® results 
obtained and subsequent engagement with specialist services for those requiring onward 
referral. 
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Chapter 3: Results 
3.01 Uptake, Incidence of CLD and Engagement in Specialist Services 
This chapter details the results of the study from the initial objectives including uptake of 
screening, prevalence of disease in the study cohort and engagement with services for those 
requiring onward referral. Analysis of the results was carried out using Excel and SPSS (version 
23). Participant demographics shall be detailed early in the chapter, to provide details of the 
cohort and incidental findings shall be documented following the results linked to the study 
objectives. Specific statistical analysis tools, where used, shall be detailed in the section with 
the relevant data. 
During the recruitment period 118 participant information packs were requested and 79 
service users took part in the study; representing an uptake of 67% of those who requested 
information. Attendance at research clinics ranged between zero to five participants. Typically, 
one to two participants attended each clinic (Appendix 11) with the Tuesday clinic attracting 
52% (n=41) of the number recruited and the Thursday clinic attracting 48% (n=38). The data 
were collected using the data collection tool specifically devised for this study (Appendix 8). 
Table 1 outlines the demographics of the 79 participants who self- selected and consented to 
take part in the study; the implications and limitations of which will be further explored in 
Chapter 4: Discussion. 
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Table 1: Participant Demographics of the 79 Participants Who Consented to 
Having a FibroScan® 
 
Participant 
information 
 
Female (n=29) Male (n=50) Total Number (n=79) 
Mean (SD) age in 
years 
46 (11)  46 (8)  46 (9) 
Currently receiving 
alcohol support at the 
community service (n 
(%)) 
24 (83%) 45 (90%) 69 (87%) 
Attending triage 
facility – first step in 
accessing support (n 
(%)) 
5 (17%) 5 (10%) 10 (13%) 
Previous detox from 
alcohol 
20 (69%) 35 (70%) 55 (70%) 
Pattern of drinking* 
(n (%)) 
Daily 22 (76%) Daily 37 (74%) Daily 59 (75%) 
Binge 4 (14%) Binge 13 (26%) Binge 17 (22%) 
Intermittent 3 (10%) Intermittent 0 (0%) Intermittent 3 (4%) 
Levels of drinking in 
units per week (self- 
reported) 
1-100  10 1-100 14 1-100 24 
101-200  11 101-200 21 101-200 32 
201-300  5 201-300 8 201-300 13 
301-400 1 301-400 4 301-400 5 
401-500 1 401-500 0 401-500 1 
501-600 0 501-600 1 501-600 1 
Unsure 1 Unsure 2 Unsure 3 
Median (IQR: 
percentile 25, 
percentile 75) length 
of drinking in years 
10 (7,20)  15 (5,20) 12 (6,20) 
Possible symptoms of 
CLD – self reported (n 
(%)) 
6 (21%) 7 (14%) 13 (16%) 
Reported risks of BBVs 
(n (%))   
12 (41%) 35 (70%) 57 (72%) 
Mean (SD) BMI of 
cohort (kg/m2) 
26.5 (5.6) 26.6 (5.2) 26.5 (5.3) 
Prevalence of cohort 
obesity  
(≥ 30kg/m2) (n (%)) 
8 (28%) 9 (18%) 17 (22%) 
*Intermittent drinking describes “four on, three off” or “five on, two off” patterns of drinking. Binge drinking describes the pattern 
of drinking where non-drinking days typically lasted more than three days weekly. 
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Of the total cohort, 13 (16%) stated they had experienced possible symptoms of CLD including 
abdominal swelling and possible jaundice, at some point in the past. No participant declared 
these symptoms as a current problem and, following assessment by the author, no participant 
displayed signs and symptoms of CLD requiring referral for further medical assessment. In 
relation to possible risks of BBVs, 57 (72%) of the total cohort reported possible risk factors.  
These include injecting drug use, tattoos in unlicensed premises, travel in areas of high 
prevalence of BBVs, receipt of blood products in the UK prior to 1991 or, more recently, 
outwith the UK in areas of high prevalence, occupational risk or high-risk sexual activity. It was 
outwith the scope of this study to further stratify these risks to higher and lower risk activity. 
The mean (SD) BMI of all was 26.5(5.3) kg/m2. This, in relation to FibroScan® result will be 
reported in greater detail later in this chapter. 
As previously discussed, the lower threshold for the FibroScan® results for this study was 
7.1kPa. Three participants elicited invalid FibroScan® results, according to the criteria for 
validity as set out by Schwabl et al (2015) where results >7.1 kPa require an IQR/Median of ≤ 
30% to be considered reliable. As with all participants, their GP was informed so they were 
aware of this participation and could refer their patient to specialist liver services, should they 
have any concerns regarding their liver health; regardless of their participation. These 
participants have been removed for the remainder of the data analysis to enable a full data set 
for those who navigated the study pathway following a valid FibroScan® result; leaving a cohort 
of 76 participants for assessment of liver disease outcomes and engagement.  
Of these 76 participants, 56 (74%) elicited a FibroScan® reading of < 7kPa, indicating no 
significant fibrosis and requiring no onward referral for further investigations. Of those 
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requiring further assessment bloods included full blood count, liver function tests, 
autoantibodies and hyaluronic acid, the results of these blood tests are outlined in Appendix 
12. Of those requiring onward referral to the nurse led clinic, 19/20 (95%) attended the nurse-
led clinic, with one participant failing to attend either of the two initial appointments at the 
nurse-led clinic but attending their GP for baseline liver bloods and thereafter the nurse-led 
service for further assessment bloods; this participant, therefore had no definite diagnosis. 
Following analysis of the blood results taken at the nurse-led liver outreach clinic by the 
Consultant Hepatologist supervising this study, none of the eight participants with a reading 
between 7.1kPa and 7.9kPa required onward referral for medical assessment. Of the remaining 
12 participants seven (9%) had a reading between 8kPa and 12.4kPa indicating possible 
significant fibrosis and five (7%) had readings equal to or above 12.5kPa, indicating possible 
cirrhosis; these participants were subsequently offered an abdominal ultrasound for further 
assessment in addition to an appointment with either a consultant Hepatologist or senior 
registrar at the RIE in order that a diagnosis could be provided and subsequent follow up, if 
needed, agreed; as per study pathway (Appendix 13). 
On completion of the study the diagnostic outcomes, as illustrated in Table 2, for the 20 
participants requiring referral to the nurse-led clinic and thereafter onward referral to 
specialist liver services was recorded. Within this group six (8%) were diagnosed with definite 
cirrhosis. One participant was discharged back to their GP following a period of alcohol 
reduction over their six-month follow up period. One participant did not engage with their 
medical assessment and therefore never received a definite diagnosis but continued to attend 
for follow up with the author in the specialist liver clinic she runs within the community alcohol 
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support service. The remaining four (5%) were diagnosed with fibrosis and remain in follow up 
with specialist services.  
Table 2: Diagnostic Outcomes of FibroScan® Screening in a Community Alcohol 
Service 
  
Diagnostic Outcomes 
 Cirrhosis 
(n) 
Fibrosis 
(n) 
Discharged 
following 
medical 
assessment 
(n) 
Nurse only 
assessment 
no further 
referral 
 (n) 
No 
diagnosis 
(n) 
No 
onward 
referral 
(n) 
FibroScan ≤7kPa 
(n=56) 
 
N/A 
 
N/A 
 
N/A 
 
N/A 
 
N/A 
 
56 
FibroScan >7kPa < 
8kPa (n= 8) 
 
0 
 
0 
 
N/A 
 
8 
 
N/A 
 
0 
FibroScan ≥8kPa 
<12.5kPa (n= 7) 
 
1 
 
4 
 
1 
 
0 
 
1 
 
0 
FibroScan ≥ 
12.5kPa (n= 5) 
 
5 
 
0 
 
0 
 
0 
 
N/A 
 
0 
 
Of the 20 participants referred to the nurse-led specialist liver clinic within the alcohol service, 
19 attended. Of the 12 patients expected to attend the RIE for medical assessment, 11 did so 
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and of 10 patients expected to attend for six monthly follow up, nine did so. All 12 patients 
referred for abdominal ultrasound attended; as summarised in Table 3. 
Table3: Engagement of Participants Requiring Onward Referral to Specialist 
Services 
 
3.02 Results Concerning Age, Length of Drinking and BMI with FibroScan® 
To assess whether data for age, length of drinking and BMI were normally distributed the 
Kolmogorov Smirnov® test was used; where a sig value of more than 0.05 indicates normality 
and sig value of 0.00 suggests violation of the assumption of normality (Pallant 2010). With a 
sig value of 0.2 both the data for age and BMI could be assumed to be normally distributed; 
while, with a sig value of 0.00 that for length of drinking could not. This, therefore, determined 
which tests were used in determining whether there was a significant difference between each 
Engagement of those 
requiring onward 
referral 
Expected number Number attended Percentage 
 
Attended nurse 
appointment at the 
research venue 
20 19 95% 
Attended first medical 
appointment at RIE 
12 11 92% 
Attended six month 
follow up 
10 9 90% 
Attended USS/CT/MRI 12 12 100% 
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of these factors and FibroScan® results in those requiring onward referral for medical 
assessment (≥8kPa) and those who did not (≤7.9kPa); with the parametric Independent t test 
being used for age and BMI and the non-parametric Mann Whitney U test being used for 
determining associations with length of drinking and FibroScan® result. 
In determining whether there was a significant difference between the age of those with 
requiring onward referral, with a FibroScan® result ≥ 8kPa and those with a result ≤7.9kPa the 
independent t test demonstrated there was no significant difference between the age of the 
group with FibroScan® result ≤7.9kPa (M=45.2yrs SD=9.6) and the age of the group with a 
FibroScan® result of ≥8 kPa (M=48.4 yrs SD=9.2). The magnitude of the difference in the means 
(mean difference= -3.2, 95% CI: -9.15 to 2.76) was small (eta squared= 0.02); where .01 = small 
effect, .06= moderate effect and .14 = large effect (Pallant 2010). 
Similarly, the independent samples t test was conducted to compare the BMI of participants 
according to FibroScan between the same groups. There was no significant difference in BMI 
between the groups with FibroScan® results <7.9kPa (M= 25.5 kg/m2 SD= 4.2) and those with a 
FibroScan® result ≥8kPa (M=30.2 kg/m2 SD= 7.4; t= 2.12, p= .055 two tailed). The magnitude of 
the differences in the means (mean difference = -4.69 CI: -9.49 to .106) was moderate (eta 
squared = .06).  
Finally, in determining possible associations between these groups and length of drinking the 
Mann Whitney U test showed no statistically significant difference between the length of 
drinking and FibroScan® result with p=0.926. 
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3.03 Incidental findings 
During the study, two of the participants who required onward referral and were subsequently 
diagnosed with cirrhosis were also diagnosed with the genetic condition haemochromatosis 
which causes excess iron storage in the liver. Neither participants were aware of this prior to 
their participation. At the end of the study they continued to engage with specialist services for 
treatment of this condition; which involves a process of bloodletting to reduce the stored iron 
levels (Sargent 2009). 
An initial assumption in designing the study was that participants would arrive for the scan 
having read through the participant information sheet and it quickly became clear that this 
could not be assumed. This, therefore, had an impact on the time dedicated to each 
participant; with the initial time slot of thirty minutes per participant approximating forty-five 
minutes while the author discussed the participant information sheet in depth prior to 
establishing that the participant was in a position to consent and proceed with the study. A 
decision was taken to make no adjustments to the study design as time slots were largely 
determined by the time negotiated with nurse management and room availability at the 
research venue; rather than an accurate estimation of sample size. This factor, in conjunction 
with recruitment numbers in this study, would inform future decisions regarding time 
allocation for a larger piece of work.  However, thirty minutes per participant to carry out the 
procedure may already be considered by nurse management or funders to be over generous 
with competing demands on practitioner time. It is therefore important that, the author is able 
to defend the amount of time afforded to either each participant in a larger study or any 
patient in the future service.  This would be easier to achieve following a rigorous evaluation of 
the intervention which aims to determine which components of the consultation were causal in 
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its success as it may not rely on each component equally (Clark 2013). However, it is vital that 
components seen as low priority are not overlooked as they may be the reason for the success 
or failure of the project (Clark 2013, MRC 2008). 
This chapter has detailed the results, both in line with the study objectives and some incidental 
findings. The data was collected using the data collection tool devised for use in this study and 
discussion of these results is provided in the following discussion chapter, and a conclusion 
offered later in the thesis.  
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Chapter 4: Discussion 
4.01 Discussion of Results in the Context of the Study Objectives, Research 
Question and Hypothesis 
As discussed in the Results chapter, seventy-nine consented individuals participated, an uptake 
of 67% of those informed of the study. Of the 79 scans performed, three were unreliable 
leaving 76 participants in whom full data collection can be completed. After scanning, 20/76 
(26%) had a FibroScan® ≥7.1kPa requiring referral on to the nurse led clinic. All 20 (100%) 
engaged in further assessment. Of those, 12 required onward referral to specialist services. 
Subsequent compliance with specialist services in this sample (n=12) was ≥ 90%. 
Uptake of routine health screening is low in areas of deprivation (Watt 2013), suggesting low 
self- efficacy, i.e. the confidence in one’s ability to exert control over their behaviour (Bandura 
1997). This could be attributed to low confidence, poor literacy and financial difficulties which 
make negotiation through the process of health care delivery and travel to appointments 
difficult (Watt 2013). Sekhon, Cartwright and Francis (2018) determined that acceptability can 
be anticipated when participants consider it to be appropriate; an important factor in 
influencing the uptake or participation in a healthcare intervention. Therefore, according to this 
definition, an uptake of 67% in this screening study, for those who received information, 
suggests that this intervention is acceptable to prospective participants in this setting; 
supporting the study hypothesis and giving an affirmative response to the study’s research 
question. Bloom et al (2018) recruited to their community-based study, offering FibroScan® in a 
community cohort of patients undergoing management for hepatitis C. Uptake in this study 
was 76% (859/1134) of those invited to attend. These two studies are not comparable, as this 
screening study is nurse-led and, other than the assessment using the data collection tool, the 
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FibroScan® was the only intervention offered. Bloom et al (2018) offered clinical assessment 
and bloodletting, in addition to the FibroScan®, with one of two Hepatologists. As previously 
discussed, without a qualitative element to their study (Bloom et al 2018) it is not known why 
the uptake they found was so high and, with a cohort already known to have CLD, it is possible 
that concern regarding their known disease, could have been a factor. However, the uptake in 
Bloom et al (2018) support the good uptake in this screening study. 
Factors influencing self-efficacy include vicarious experience and verbal persuasion (Hayden 
2019).  As this study took place in an alcohol recovery centre, most potential participants had a 
level of contact with support staff, whether it be to support them in their recovery or to 
complete their initial assessment towards enrolment in a recovery plan. Therefore, it is feasible 
that verbal persuasion, or encouragement, took place and has had an influence on the uptake 
of screening, as was acknowledged when devising the recruitment strategy. This, in conjunction 
with vicarious awareness of the intervention through the participation of, or discussion 
between, service users could have influenced the self-efficacy of those who took part.  In 
addition, the engagement with alcohol services of those who self-selected to take part in the 
study appears to demonstrate a level of self-efficacy in this cohort, which, subsequently, could 
have accounted for this level of uptake. 
According to the Health Belief Model a cue to action, or factor that starts a person on the way 
to changing their health behaviour (Hayden 2019) is influenced by their perceived threat of 
disease. This perceived threat is guided by an individual’s assessment of their chances of 
getting the disease (perceived susceptibility), and their judgement of its consequences to them 
(perceived severity) (Skinner, Tiro and Champion 2015). In addition to personal attributes such 
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as age, gender and sociodemographic status a modifying factor to this perceived threat is 
knowledge and awareness of the health condition (Skinner, Tiro and Champion 2015).  
In this study, the cue to action could be the study information posters in reception, the 
conversation between potential participants and their support worker or peers. Through their 
engagement with alcohol support services, those who participated in the study are likely to be 
aware of the effects of alcohol on the health of the liver, through access to health promotion 
materials and consultations with support staff in the service. This knowledge and awareness 
may be one of the modifying factors influencing the level of uptake in this cohort (Hayden 
2019, Sharma 2011). Self-efficacy is an important factor in the Health Belief Model, particularly 
when considering the individual’s confidence in their ability for behaviour change, despite 
possible perceived barriers (Hayden 2019).  
Burnham et al (2014) explored knowledge, attitudes, behaviour and barriers to care amongst 
patient with CLD through conducting three separate one-time focus groups sessions with a 
total of 13 participants with CLD, in the USA. While some barriers, such as lack of health 
insurance and high cost medical care, are not transferable to the UK, where healthcare is free 
at the point of care, other factors could be considered as relevant. These included a lack of 
knowledge about CLD and perceived stigma from staff and peers (Burnham et al 2014). This 
further emphasises the importance of knowledge, as a modifying factor in engagement with 
health interventions. Burnham et al’s (2014) cohort were known to have CLD, as opposed to 
the group in this study who, at time of uptake, had concerns that they have a risk of CLD. This 
becomes increasingly relevant for the engagement of the group who required onward referral 
to specialist services following a raised FibroScan® result with indications of possible CLD. While 
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not comparable in design, as previously discussed, to the study by Bloom et al (2018) this 
engagement for those requiring onward referral is higher than that in their study of 55% 
(28/233). As this is a convenience sample of participants, already attending this alcohol support 
service it can be assumed that concerns regarding possible stigma from staff and peers have 
been allayed through their experience of this service to date. High engagement with specialist 
services for those requiring onward referral thereafter suggests that trust in the service was 
gained through their contact with the author during screening and follow up appointment, for 
those who required it. This is consistent with the aim of nurse led services to provide, facilitate 
and expand access to quality care to an often vulnerable population who may not otherwise 
access care in mainstream services (Kleinpell et al 2014).  
Without the benefit of having carried out a qualitative piece of work, where the participant 
experience could be understood it may be assumed that, at least, for those who participated in 
the study, perceptions of stigma from staff both in the recovery centre was low, for them to 
engage with screening in the first instance. Thereafter, following contact with the author during 
screening, it would appear that an element of trust in specialist services was gained. 
Alternatively, it could suggest that, in this self-selected group an existing level of trust was not 
damaged by this process. This is demonstrated by high levels of engagement for those 
requiring onward referral and does not account for those who did not participate in screening. 
This is acknowledged as a limitation.  
The Theory of Planned Behaviour suggests that attitudes to a behaviour and subjective norms 
(behaviour perceived as favourable to people with influence over an individual) (Hayden 2019) 
influence behavioural intention with the concept of perceived behavioural intention, a 
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characteristic of TPB, considered similar to self-efficacy (Montaño and Kasprzyk 2015). 
According to Marks et al (2015), intention and self-efficacy are the best predictors of behaviour 
change; particularly when combined with facilitators to change such as the aforementioned 
possible verbal support from peers and staff. Such support could influence the subjective norm 
of potential participants. This is a self- selected group who, through their attendance with the 
alcohol service, demonstrated a level of self-efficacy and motivation to change their behaviour 
in a setting where support is available. In this respect this screening intervention appears to be 
in the right place at the right time. 
As participants were recruited through a “drop in” system, it is beyond the scope of this study 
to determine the number of potential participants who did not request research information, 
and their reasons for this, and is acknowledged as a limitation. The study results on 
acceptability, as indicated by uptake, are consistent with other studies demonstrating the 
acceptability of offering FibroScan® as a screening tool in community drug services (Foucher et 
al 2009, Marshall et al 2015, Thurnheer et al 2015) and would appear to show it could be an 
effective way of encouraging initial engagement with specialist liver services. 
As discussed, in Chapter 2: Methods, in working with a group who are drinking to hazardous, 
harmful or dependent levels (Scottish Government 2012) participants may attend in an 
intoxicated state. Indeed, this happened with two participants bringing further challenges to 
the author in determining whether or not they were able to participate in the study. Informed 
consent, determined by establishing that participants are informed on the process and 
implications of the study, are competent to consent and are taking part on a voluntary basis is a 
vital element in recruitment (NHS Scotland 2014). One participant argued with the author that 
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there was no requirement in the participant information sheet for sobriety indicating he had 
clearly read it and seemed to have a good understanding of the study. By coming forward for 
the study he was also displaying tacit consent through voluntary participation (Tappen 2011). 
However, whether he was competent to consent was unclear in this situation as, even though 
he seemed keen to have the scan taken he may not have been aware of the sensitivity of some 
of the questions asked through data collection. While in an intoxicated state he seemed easily 
distracted and emotionally labile. He was argumentative with the author one minute and 
tearful the next. Ultimately, the concern for his vulnerable state and a question mark over his 
competence to take part was the rationale behind asking him to return in a sober state. In 
returning sober this participant appeared anxious and displaying mild symptoms of alcohol 
withdrawal. A decision was taken to agree to his participation in the study as he had made the 
effort to return for the FibroScan® thereby displaying voluntary participation (NHS Scotland 
2014). Again, his knowledge of the study was good and in returning he had displayed a 
competence in deciding to attend (NHS Scotland 2014). Indeed, this participant was very keen 
to have the scan taken. Unfortunately, this scan elicited an unreliable result. While a likely 
cause for this was due to a BMI ≥30kg/m2 and a fatty thoracic belt (Castera, Forns and Alberti 
2008) another reason for the unreliable result may have been the tension in his intercostal 
muscles due to mild withdrawal (Trabut et al 2015). This episode served to reaffirm the 
potentially vulnerable status of this cohort and the rationale taken in deciding on a low 
maintenance recruitment strategy (LoBiondo-Wood and Haber 2014). Had the author or 
recovery staff approached potential participants, regarding the study, in reception informed 
consent may have been more difficult to establish; especially if there is a possibility of them 
being in an intoxicated state when approached.  
64 
 
The data collection tool was designed to facilitate a medical and family history for participants, 
in order that factors increasing their risk of CLD can be documented and further assessment 
offered, where appropriate (Snadden et al 2013). Despite having extensive experience of taking 
sensitive medical and lifestyle histories, involving discussion regarding sexual history and drug 
use, the author was a relative novice in taking a comprehensive alcohol history. In designing 
the study and, as discussed in Chapter 2: Methods, it had been decided that the validated 
alcohol screening tools, such as AUDIT C and FAST (PHE 2017) would not be utilised with this 
cohort. These are used as a screening tool to identify those who are drinking to hazardous, 
harmful or dependent levels while the targeted group in this study have already acknowledged 
they are drinking to such levels by attending the service for support in reducing their alcohol 
intake. Indeed, in engaging participants whose attendance at the research clinic reflects their 
concerns regarding their alcohol intake on the health of their liver assumptions were made that 
this would be a relatively straightforward component in the data collection process. In 
commencing data collection, it became evident that more was required than asking “how much 
do you drink in a week” and converting it to units of alcohol, with 1 unit equal to 8g of pure 
alcohol (NHS 2019). Responses ranged widely from participants who were abstinent to 
participants who drank a varying amount each week with no standard amount in any one. 
In their systematic review of the literature to evaluate the reliability and validity of self-
reported alcohol consumption measures among adults, Mckenna et al (2018) assessed the 
psychometric properties of the short-term recall, quantity-frequency and graduated frequency 
methods of recording alcohol intake. As the name suggests, short-term recall determines the 
amount of alcohol consumed within a recent defined period and was the method of data 
collection originally planned for this study, as mentioned in the previous paragraph. The 
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graduated frequency method of data collection groups the number of drinks consumed per 
occasion. For example, it would ask of the interviewee how often, in the last 12 months, they 
drank over 12 units, then how often they would drink over 8 units and continue the 
questioning with reducing amounts. The quantity-frequency method asks questions regarding 
“usual” alcohol to estimate frequency and volume consumed. Using the consensus based 
standards for the selection of health measurement instruments (COSMIN) where they derive 
ratings of poor, fair, good or excellent for each checklist item relating to each psychometric 
property McKenna et al (2018) acknowledge that not all psychometric properties of each 
measure were assessed consistently in the literature. Despite this, they evaluated the quantity-
frequency measure as that which performed best in psychometric terms and most likely, of the 
three measures, to produce reliable and valid measures of alcohol intake in a general 
population survey. They suggest the use of caution in using this measure in a population of 
dependent drinkers (McKenna et al 2018). This follows the recommendations by Toneatto, 
Sobell and Sobell (1992) who suggested there might be discrepancies participant’s alcohol 
history, depending on memory reliability, influenced by how much alcohol has been consumed 
on the day of questioning, and whether the participants were confident of confidentiality in the 
questioning. With this in mind, the author ensured she reinforced the confidentiality afforded 
to participants in taking part in the study. In addition, she decided to adapt the quantity-
frequency mode of questioning for this study. To accommodate the fact that participants were 
attending for support with current or past drinking and that some participants were currently 
abstinent, they were asked “When drinking at your heaviest levels, how much would you drink 
in a typical week”. The aim of doing this was to elicit a more accurate history of lifetime alcohol 
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use to date; in particular heavy alcohol use which, even in historic cases, could have had a 
serious impact on their current liver health (Muir 2015). 
In order to illustrate the UK sensible drinking measures, Gill and O’May (2007) asked 
employees from four sites in Scotland to pour their usual measure of wine or spirits and to 
estimate the number of units in this volume. Typically, drinks poured were 2.05 units of 
alcohol, with only 27% of participants estimating the unit content within 10% of its actual 
value. This correlates to an earlier study by Gill and Donaghy (2004) where a sample of the 
Scottish public were recruited from three employers and were asked to pour their usual 
measure of wine and spirits. In their study, the mean measure for wine was 1.92 units, while, 
for spirits it was 2.3 units; challenging an often implicit assumption in consumption surveys that 
one measure is equal to one unit of alcohol. 
To further quantify weekly alcohol units, in this screening study therefore, participants were 
asked what a typical week’s intake would be with regards to the type of alcohol consumed and 
the typical volume consumed, in order that the author could calculate the units by referring to 
the unit calculator provided by Drinkaware (2019). 
Some participants claimed to binge drink while others drank on a daily basis. While this seemed 
straight forward in describing their drinking behaviour as either “binge” or “daily”, it posed the 
question of how to describe drinking which was neither binge nor daily. Some participants 
stated that they drank four days on and three days off on a regular basis, the author decided 
that the group who drank regularly on some days during the week, such as four on three off, 
should be considered a separate group. In considering the development of the codebook for 
analysis of data using the SPSS (Pallant 2010), at the end of the study, it was decided to 
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describe this drinking pattern as “intermittent”. Data from the study showed that, out of 79 
initial participants, 59 (75%) of the cohort described themselves as “daily” drinkers, 17 (22%) as 
“binge” and 3 (4%) as “intermittent”. 
It also became apparent, through discussion with participants, that complete abstinence from 
alcohol was not the goal of all participants. This was in contrast to the author’s past experience 
of working closely with PWIDs who generally aimed for complete abstinence when attending 
support services. Denvir (2012) discusses issues which can arise if the practitioner forgoes their 
own clinical evaluation in favour of the patient’s self- evaluation due to a desire to build 
rapport; a common problem in lifestyle history taking. In taking a harm reduction approach it 
would seem reasonable to support participants in reducing alcohol intake. However, complete 
abstinence is optimum for improving liver health, especially where CLD is established (Williams 
et al 2014). This highlighted the importance of finding a balance between developing and 
maintaining a good rapport while delivering the message that their health outcome could be 
improved through reducing their drinking with the aim of abstinence even for those who may 
ultimately be diagnosed with cirrhosis. 
At a time when mortality from CLD, including cirrhosis, has increased by 500% since 1970 in the 
under 65 age group (Williams et al 2014), the mean age of 46 years in this cohort of 
participants seems optimal for consideration of screening. With male mortality rates for CLD 
being almost twice as high as those reported for women (ONS 2017) the proportion of male to 
female attendees for 63% to 37% would appear to be representative of this population.  
Participant alcohol histories confirmed this to be a heavy drinking group, as targeted; with self-
reported alcohol intake of over 100 units per week in 76% (45/76) of participants. Those with a 
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FibroScan® reading ≥ 7.1kPa and < 8.0 kPa did not require onward referral once their blood 
profile was assessed by a Consultant Hepatologist (AMacG); supporting studies using a 
threshold of 8.0kPa (Harmen et al 2015 and Roulot et al 2010) and adding to the literature 
regarding the lower cut off for FibroScan® in general screening. 
Obesity is one of the most common causes of CLD through fatty infiltration of liver cells (Muir 
2015). Levels of obesity are highest for those living in deprived areas (ScotPHO 2017), often due 
to poor diet and lack of exercise. Within this cohort the prevalence of obesity was 21.1%, while 
the current prevalence of obesity is 29% in the general population of Scotland (ScotPHO 2017). 
The portable FibroScan® device used in this study (FibroScan® 402) could not support an XL 
probe. While only three scans were unreliable, according to criteria in Schwabl et al (2015), 
each of these participants had a BMI ≥ 30kg/m2. This is consistent with the findings of (de 
Ledinghen 2012) and it would, therefore, seem advisable, given the level of obesity, that an XL 
probe is available in future.  
Consistent with the asymptomatic nature of liver disease no participants described or displayed 
signs or symptoms (Muir 2015) and yet, as outlined in the Results chapter, one male participant 
was referred for medical assessment with an elevated FibroScan® result was subsequently 
diagnosed with cirrhosis in addition to haemochromatosis, a genetic disorder of iron overload 
in the liver known to affect approximately 1/200 of the British population, but thought to affect 
1/5000 (BLT 2018). One female participant, who required onward referral for a raised 
FibroScan® result was also diagnosed with haemochromatosis, in addition to significant liver 
fibrosis. Neither participant had previously been tested for this genetic condition, which could 
have life limiting effects had it continued to be undiagnosed (Sargent 2009) or, subsequently, if 
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the participants did not engage with its recommended management which includes regular 
bloodletting to remove the excess iron from the circulating blood (BLT 2018). However, these 
participants did engage with specialist services and subsequent management of their condition; 
illustrating an incidental advantage to them of engaging in the study.  
With 95% (19/20) participants attending the nurse appointment at the research venue, 92% 
(11/12) attending their first medical appointment in acute services, 90% (9/10) attending their 
follow up at six months and 100% (12/12) attending for further assessment with ultrasound, CT 
or MRI. This encouraging engagement in specialist services further demonstrates self-efficacy 
and high motivation in the cohort, as supported by Health Behaviour Theory (Sharma 2011).  
Sheron et al (2013) devised a serum panel test known as the Southampton Traffic Light system. 
This system uses a combination of the fibrosis markers hyaluronic acid, collagen P3NP and 
platelets. Results are colour coded to red for possible fibrosis/cirrhosis, amber for possible 
fibrosis and green indicates negative for fibrosis.  Their prospective feasibility study aimed to 
determine the feasibility of community screening for liver disease and determine whether 
feedback on liver risk can increase the number of subjects reducing alcohol consumption. This 
study was conducted across nine GP surgeries across Hampshire, Wiltshire and Dorset, UK, with 
a high initial sample size (n=4630). Sheron et al (2013) randomly selected patients aged 
between 25 and 54 from the GP databases and posted invitation letters, which included an 
AUDIT questionnaire. AUDIT scores of <8 were assessed as low risk for harmful drinking, those 
between 8-15 were assessed as consuming alcohol to hazardous levels while those with a score 
of ≥16 were assessed as drinking to harmful levels. Those respondents with an AUDIT score ≥8 
were considered to be drinking to hazardous levels (WHO) and were subsequently invited to a 
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nurse led research clinic where blood was taken, and results recorded as per the traffic light 
system. Participants were informed of their results in writing and a further AUDIT 
questionnaire sent one year later to establish their drinking levels. In total 4630/9836 (47%) of 
questionnaires were returned with responders being significantly more likely to be older, 
female and with low deprivation scores.  Of the 1037 who responded with an AUDIT score of 
≥8, 393 (38%) attended the nurse led research clinic for further assessment. Of those, 303/393 
(77%) responded to the follow up questionnaire at one year. Sheron et al (2013) state that, 
overall, the mean AUDIT score had reduced from 13 to 11, with the one-year changes being 
significantly greater in the red/amber group i.e. those drinking to more harmful levels. 
However, as Sheron et al (2013) acknowledge, the non-responders had significantly higher 
baseline AUDIT scores and alcohol consumption and should they have been included and 
considered to have no change in AUDIT score, the magnitude of effect would be less significant. 
Sheron et al (2013) found that, in the group with baseline AUDIT >15 the change in AUDIT score 
by more than one grade was significantly higher in the red/amber group than in the green 
group. Sheron et al (2013) conclude that feedback about liver health may be a useful prompt 
for behaviour change; with the biggest reductions in drinking being seen in the group with 
heaviest drinking behaviour up to one year following the intervention. This suggests that 
combining a screening intervention for liver disease with ongoing support in alcohol recovery, 
as in this screening study, should have a positive impact on behaviour change. However, in 
their study Sheron et al (2013) set, as an exclusion criterion, those with severe mental health 
problems; thus introducing possible bias in the results by excluding a potentially heavy drinking 
and recidivist group (Williams et al 2014). The recruitment strategy for Sheron et al’s (2013) 
general population study differs from this screening study targeting a cohort with a current or 
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past history of drinking to hazardous or harmful levels. However, in light of their findings, the 
early engagement with assessment, feedback and follow up in specialist services in this study 
was extremely encouraging as a possible predictor of health behaviour change. In addition, this 
is in line with the findings from Foucher et al (2009), discussed in the literature review, who 
concluded that uptake of hepatitis C treatment in a group who previously had not engaged, 
was a direct result of having a FibroScan®. However, it is important to continue research 
beyond this study to determine what, if any, impact this type of intervention has on the longer-
term drinking behaviour of this or a similar cohort. 
The author was concerned that a result ≤ 7kPa could be interpreted by the participant as giving 
them permission to continue drinking to harmful levels; as there was no indication of liver 
disease, so far. Nested within Sheron et al’s (2013) study was a qualitative piece of work, where 
participants identified as drinking to harmful or hazardous levels were asked to take part in an 
interview. This was in order that their experience of taking part in the study and their 
understanding of its delivery and process of screening for alcoholic liver disease could be 
explored. In total, 210 participants were approached by the research team. Of those, 48 
responded, and 30 interviews took place before saturation was reached (Eyles et al 2013).  
Of interest, to this screening study was Theme 2, which assessed whether alcohol blood testing 
was a catalyst for change, in terms of amount of alcohol consumed. Of particular interest to the 
author, was the response of six out of eight participants who were drinking to harmful or 
hazardous levels and had received a negative result on the serum panel test, for fibrosis. These 
participants stated they had not altered their drinking habits in view of what they perceived as 
an indication from the results that they could continue drinking to their previous levels. 
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Researchers for this study were concerned that they had, in effect, issued a license to drink or 
“green light” for drinking to harmful of hazardous levels. They decided that, when giving a 
negative result in the future, the serum panel test would be altered so that, when giving 
feedback to harmful or hazardous drinkers negative, which was previously green on the panel, 
would be amber. Amber, which originally had indicated some degree of fibrosis would be 
changed to red, for this group. Red, which indicated a high likelihood of fibrosis would 
thereafter be maroon or black. Whilst, visually, this may be a more effective way of 
communicating that there was some degree of risk, regardless of blood result, through their 
high levels of drinking, Eyles et al (2013) acknowledge that, in part, it may be also an effect of 
having the results being imparted to participants by the GP rather than liver specialist. There 
may have been some confusion, on the part of the GP as to what the negative result actually 
meant, and they aimed to address this for further interventions with further support being 
offered to GPs on the information which should be given to patients in similar situations in the 
future (Eyles et al 2013). The advantage the group in this screening study had, over those in the 
study by Eyles et al (2013) is that each participant had the opportunity to speak with an 
experienced liver Hepatology Nurse Practitioner at the time of their FibroScan®, giving the 
opportunity for health promotion to be tailored to the individual participant (Presky et al 
2018).  
In their observational cross-sectional patient survey, Presky et al (2018) considered possible 
factors influencing beliefs held by patients with alcohol related liver disease and non-
adherence to their medication. In their study, the targeted sample were patients attending a 
liver outpatient clinic with already known alcohol related liver disease, thereby differing from 
the sample in this study who are, as yet, unaware of the health of their liver. However, one 
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similarity between the groups is alcohol as a factor in either their current condition or concerns 
regarding their health. Presky et al (2018) found that tailoring information on their health 
condition to the individual with alcohol related liver disease is likely to increase their likelihood 
of engaging in ongoing management. It, therefore, fell to the expertise of the author to tailor 
health promotion information in the context of individual participant history and FibroScan® 
result; highlighting the importance of working with their self-efficacy and motivation to reduce 
the alcohol intake of those who elicited a normal result. In his writing on perceived self-efficacy 
(Bandura 1997) suggested that information highlighting potential health losses are more 
effective than those emphasising health benefits, suggesting the benefits of advice on 
maintaining liver health through a continued attempt to reduce alcohol intake and discussion 
of other factors, elicited through data collection, pertaining to the individual participant. There 
was no scope to address the question of how a normal result impacted on participants’ 
motivation to change behaviour; this could be further investigated in a follow on, longitudinal, 
qualitative study. 
In complex health interventions (MRC 2008) their success, or otherwise, is dependent on many 
factors and it is important to consider optimisation of the intervention, in order to progress it 
to an embedded service or further research (Levati 2016, MRC 2008). Sermeus (2015) 
acknowledges that an increasing number of components characterising interventions leads to 
them being harder to implement and it is important, not only to establish the key components, 
but also the inactive components in the intervention. In this study, one possible key factor is 
the acceptability of the non-invasive, painless FibroScan® device which gives an immediate 
result; as opposed to blood tests which can be painful and do not elicit results immediately. In 
addition to this the author offered the FibroScan®  and also delivers the liver clinic at the 
74 
 
community alcohol service and, in this respect, is motivated to work with harder to engage 
groups and familiar with some of the challenges posed (Watt 2013). In particular, this is 
reflected in the recruitment process where participants were not approached directly by the 
author as it was important that vulnerable, potential participants should not feel coerced into 
taking part. The ability of the nurse to engage with the participant’s own motivation in 
considering changing their behaviour (Lau-Walker et al 2016) and continuity of care offered by 
seeing the same nurse in the initial stages of the pathway may be a crucial factor in gaining the 
trust of participants and may also account for the level of engagement seen. As discussed, 
another key component may be the choice of venue, the influence and support of staff and, 
importantly, the self-efficacy and motivation of the self-selected cohort of participants.  
This screening study was a fixed term study, not designed to assess whether the encouraging 
level of engagement continues and whether the lifestyle changes required for improving the 
participant’s liver health were instigated and continued over a longer period of time and this is 
acknowledged as a limitation. Further work is required in determining the key components of 
screening and to gain insight into its acceptability and reasons for the encouraging level of 
engagement. This may be possible through a qualitative study, collecting data using one to one 
interviews with consented participants to understand the participant experience. In addition, a 
longitudinal study, designed to monitor changes in lifestyle behaviour beyond the six months 
post screening in this study, would help to establish whether engagement and lifestyle changes 
were sustained.  
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4.02 Dissemination of findings  
For a study to have impact, in terms of support for funding for future research and possible 
service development, it is important it be effectively disseminated (Reed 2018). Through his 
Persuasive Communication Matrix, McGuire (2001) suggests a theoretical framework for 
effective dissemination, constructed around five variables. These include the source of 
communication, the message being communicated, channels of communication, characteristics 
of the audience and the setting for the dissemination. For this study, the source would be 
relatively inflexible and include the author sharing key aspects of the research. However, the 
message, channels, characteristics of the audience and the setting were aspects of 
dissemination, which, for this study were much more flexible. While the key message of the 
study continued to revolve around the study findings, additional messages would be 
dependent of the characteristics of the audience and will be explored later in this section. 
Informing and gaining the support of interested parties, or key stakeholders early in the design 
process increases the chance of the study being impactful and implementation being sustained 
(Schell et al 2013).  Delaying dissemination until the data collection is complete and the results 
have been analysed risks missing possible buy in from key stakeholders at an early stage and 
slow or halt progress later in the process (Reed 2018). Ultimately, this provided a challenge for 
the author in being able to disseminate information regarding her study without compromising 
the integrity of the results and her intellectual property (Reed 2018). In line with McGuire’s 
(2001) framework, it is important that an appropriate audience are selected for this 
dissemination in order that, to gain support from stakeholders, it is targeted at those who 
could help take it forward, either financially or through their professional network.  
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In the case of this study, therefore, the first point at which to disseminate the research idea 
was the call for applications for funding for the portable FibroScan® device in the early stages 
of the design process, as discussed in the Chapter 1: Introduction. At this point, the study idea 
was very new to the author and the full participant pathway had not yet been decided; in part, 
because it was not known whether she could secure the funding for a FibroScan® device. Whilst 
this was her first preference for engaging participants attending the alcohol service, she was 
aware the device may not be secured and that she may need to return to the drawing board in 
order to determine what, if any, other intervention may be feasible. Any concerns she may 
have regarding the security of her intellectual property, at this stage, was insignificant 
compared to her drive to take the study forward. Without divulging her idea to the audience at 
the NHS Innovation Board, in the first place and risking another party taking her idea forward 
as their own, the study may never have got off the ground (Reed 2018). However, this was 
carefully assessed by the author as, in reality, the situation where, in this environment, 
someone could take this idea as their own, was unlikely due to the need for training in using 
the FibroScan® device and the lack of skill in this area outwith the liver unit.  
Following her successful presentation to the NHS Innovation Board, the next opportunity for 
dissemination of her idea for the study arrived with the call for applications for funding towards 
doctoral study from a new funding body, NHS Research Futures. Whether the study could go 
forward, at this stage, was not in question, as the author had already secured funding for the 
FibroScan® device and by then, had successfully negotiated time resource and use of a venue 
for the study. However, the author was keen to use this opportunity to secure further academic 
support in order to raise the standard of this piece of research, which she did not initially 
design with a doctorate in mind. In disseminating information on the study to this audience, 
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including a NHS Lothian partnership representative, a clinical nurse manager responsible for 
research and adviser on nursing, midwifery and allied health professional research, the 
message was one of the potential impact of the intervention on possible service development 
and its concordance with current policy drivers, such as the Health and Social Care Integration 
(Scottish Government 2013) and the Scottish Government’s 2020 vision (Scottish Government 
2017). With a positive outcome to her application came funding for doctoral studies and 
contracted study time. This gave her time resource and academic support in improving, where 
it was required, the rigour of the study.  
While, at the time of her application the time resource and funding towards the fees for her 
doctorate, were the main drivers for the author in applying to NHS Research Futures, it has 
become apparent over the course of her studies how much more support it has given her. In 
engaging the support and funding from NHS Research Futures, the author joined a wider 
research network of fellow doctoral candidates working within the NHS and a wider network of 
doctoral candidates from other disciplines through her network at the university graduate 
school. Through this professional network, she has taken the opportunity for discussion and 
dissemination of her research ideas to a wide range of disciplines both within and outwith the 
health arena. In the early stages of dissemination, the message in this setting and to this 
audience focused on the research process, theoretical underpinnings and process of analysis. 
This dissemination opportunity has provided valuable formative feedback (Biggs and Tang 
2011) for the author in enabling her to hear the critique of her work from this network and 
defend her research in what she considered a “safe” environment. In this setting, if she made 
an error, it would not affect the outcome of her research but was a learning opportunity where 
possible changes to the research process were considered prior to more formal dissemination 
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to other professional audiences. In this respect, the author has had the opportunity to increase 
the depth of her learning in research design. Discussions within an inter-professional audience, 
such as these, not only enabled the author to consider aspects of her research from the 
viewpoint of her fellow students but also from a non-nursing perspective; ultimately improving 
her ability to strengthen her argument when faced with challenges regarding her study. In 
particular, this experience enabled the author to develop skills of dissemination to a non-
healthcare audience. Importantly, this ensured she considered, where possible, that the 
information was accessible to a range of audiences (INVOLVE 2015); skills she would require 
later in her doctoral career. Examples of such dissemination include oral and poster 
presentations to two doctoral conferences at Queen Margaret University.  
During one doctoral conference on the 28th April 2016, the author gave a poster (Appendix 14) 
and an oral presentation. The attendees at this conference voted on the best poster displayed 
that day, with the author winning first prize on this occasion. During a subsequent doctoral 
conference, the author took the “5 minute challenge”; an exercise in distilling the key factors of 
a piece of research into a five minute presentation, using only one power point slide, in 
addition to the title slide. As was the intention, this exercise enabled her to concentrate on the 
important messages of her study; through developing vital skills in focusing the information to 
the minimum needed to relay the key points while still ensuring the resulting presentation was 
unequivocally outlining her study. This exercise helped the author later on in her research 
career when writing for publication; in particular, when distilling information for writing 
abstracts for conference or publication, which typically required no more than 300 words.  
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On two occasions, the author presented the study to the liver unit. The first occasion was early 
in its design and prior to data collection, with the aim of ensuring transparency of the study. 
This was with the aim of gaining more buy in from the department, as a whole, in light of the 
resistance she faced from some of her nursing and medical colleagues in taking this study 
forward. This is consistent with Reed (2018) who suggests tendering for support from key 
stakeholders to ensure buy in and increase the likelihood of the sustainability of the study. As 
noted in Chapter 1: Introduction, this presentation came after the initial resistance she 
experienced from colleagues and once ethics approval for the study had been obtained. The 
author’s rationale for this, at the time, was to protect this as a nurse-led initiative. As a 
relatively new member of the liver unit, and as an inexperienced researcher she had concerns 
that, should senior medical colleagues, more experienced in research, become involved too 
early in the design phase, she may be convinced to alter its focus to a more medical approach.  
However, in the hope of securing more support for the study at that point, she was careful to 
emphasise the outcome of the study looking at incidence of disease; altering the focus of the 
dissemination message for this medical audience (McGuire 2001). As a newcomer to the liver 
unit, the author was unaware of some of the dynamics between some senior personnel, which, 
now with more experience in the unit, may have altered her decision on who to secure buy in 
from for the study from an early stage. In this respect, her research of the key stakeholders to 
represent the study could have been more extensive (Schell et al 2013). However, as the first 
nurse led study to take place in this unit, this was uncharted territory for even the most 
experienced of nurses in this area. Ultimately, the author had, at that stage, managed to secure 
enough senior support to ensure the study went ahead. 
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Later, when presenting the preliminary data of the study to the liver unit and knowing the 
audience to be largely from the medical side, she again emphasised the incidence of disease in 
the study cohort. She reported this with the blood results of those requiring onward referral 
through creating a slide with a table for discussion during the presentation in order to 
demonstrate the concordance of FibroScan® results with that of the serum fibrosis marker, 
hyaluronic acid. In this way, she had again, created a message which was likely to make the 
study more interesting to her medical colleagues (McGuire 2001). This slide did generate 
discussion on the day, illustrating that it had indeed caught their attention. While feedback 
regarding the study from her medical colleagues was more cautious following the first liver unit 
presentation, feedback from the second presentation was much more positive and supportive, 
with suggestions from some senior medical colleagues of the need for discussion in taking the 
findings from this study forward as a service development. This will be further explored in a 
later part of this chapter, looking at the impact of the study. 
During the latter part of her research, the author took the opportunity to become involved in 
the Beltane Knowledge Network “Cabaret of Dangerous Ideas”. This initiative, funded, by a 
network of universities in central Scotland, has the aim of encouraging academics to engage 
with the public by presenting their research or topic of expertise in an accessible way during a 
one-hour show at the Edinburgh Festival Fringe (Beltane Network 2019). In applying to take 
part in this initiative, the author was invited to attend workshops or “Boot camps” which 
include creating material for a one-hour show.  Training in how to engage an audience and use 
a microphone were also part of the training for those who signed up. In addition, a comedian, 
who used her experience of performing to ensure the show ran smoothly, hosted each show. 
This included helping to keep the light hearted, funny yet informative emphasis required by the 
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Beltane Knowledge Network through asking questions, helping to engage with the audience 
and deal, where necessary, with any hecklers. Audiences paid to attend these shows, with all 
the money going to the Beltane Network. In addition, each “performer” was required to pay a 
£200 fee for promotion of their show in the Fringe programme. The author applied for and 
secured this from the Centre for Applied Social Sciences at Queen Margaret University. 
The show was called “Shiver me Liver” to reflect the effect of elastography on the liver. In 
attending the “Boot Camp” and through discussion regarding the content of her possible show, 
the author soon realised that within this academic group from a variety of backgrounds, 
knowledge of the liver was scant, with many in the group having no knowledge of where the 
liver was located. This gave her the idea of using the first 30 minutes of the show as more of an 
educational opportunity regarding the liver and liver health. With the comedian being available 
to help in whatever way the show required, the author decided to start the show with a game 
she devised. The comedian agreed to wear a T-shirt and a headband with Velcro strategically 
placed in various places. Three organs were crafted, a brain, a heart and a liver, each with 
Velcro attached. The author then invited members of the audience to site the organs on the T-
shirt, corresponding to where the organ is located in the body. The rationale behind this was to 
illustrate where the liver was in a fun way and provide a starting point for further teaching on 
its functions and pathophysiology through active learning (Gibbs 1988). With the emphasis on a 
lighthearted delivery, the author decided to disseminate further information through a quiz; 
encouraging active learning through discussion (Brookfield and Preskill 1999). In this respect, 
the audience were participating in an educational experience, where the author illustrated, 
visually, facts regarding the liver. These facts were then discussed in the larger group, where 
they had the opportunity to learn vicariously from others’ learning (Jacques and Salmon 2007). 
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Following this introduction to the liver, the next part of the show centred on the research 
findings. One aspect of taking part in this event, which challenged the author, was the need to 
ensure there was no compromise of her results, ethics or research process. The research study 
was a complex and important piece of work; it was important this was not undermined in doing 
this show. In undertaking this piece of research and having ethics approval granted by South 
East Scotland Research and Ethics Committee the author had agreed to ensure beneficence, 
therefore to do no harm (Hack and Gwyer 2013). Ultimately, she was required to protect the 
participants in the study and challenged in this by taking part in this knowledge exchange 
opportunity in a show with a comedian. It was imperative that any fun or comedy involved in 
disseminating this study should not be at the expense of the participants. It was also important, 
not only to protect the participant’s anonymity and confidentiality, but also to ensure there 
were no anecdotes used which would display them in an unfavourable or comedic way. 
Ultimately, it was important that the show was conducted in a manner which was inclusive and 
respectful to participants (INVOLVE 2015). 
This show was taking place in a licensed premise where they served alcohol. It would be 
reasonable to anticipate comments regarding this during the show, particularly as the research 
study had taken place in an alcohol support service. Therefore, it was important for the author 
to ensure she was not seen to be complicit in any comments regarding the benefits or 
otherwise of alcohol. The alternative also being true, in that, as this was an entertainment 
show she could not engage in advice regarding the risks of alcohol in any way which could be 
perceived as judgmental (Reed 2018) and was mindful of keeping any advice there was 
regarding alcohol to answering specific questions by the audience or within what was the script 
for the show. In this respect the author had to act within her boundaries as a nurse, where she 
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must always represent the nursing profession (NMC 2015) and the liver unit; an essential 
quality in the NHS Leadership model (NHS Leadership Academy 2013). In addition, as a doctoral 
candidate and researcher she was also representing her university. Mindful of these challenges 
she ensured that, when writing the content for the show she considered how participants of 
her study and her NHS management would feel if they were in the audience. In taking this 
forward, she aimed for transparency as far as possible. She could no longer approach individual 
participants from her study, now that it had finished. Ethics approval had not been sought for 
this at the start of the research process. However, the author displayed posters for the event in 
the original research venue, in order that participants could be alerted to the fact the show was 
taking place and had the opportunity to attend should they be interested. In addition, she 
displayed posters for the event in her place of work and invited the management and staff 
from the research venue, NHS management and the ethics committee by email.  
In devising the script for the second part of the show, where she discussed her research, she 
chose a format that ensured the information emerging from the quiz in the first half served as 
the background i.e. functions of the liver, pathophysiology, epidemiology of liver disease and 
introduction to the FibroScan® device.  This part of the show followed a similar format to the 
first in that, rather than telling the audience the results of the research in a didactic way, the 
author chose to present an overview of this information in the format of a discussion. So, 
rather than telling them what the prevalence was for uptake and engagement for those 
requiring onward referral for the intervention she instead gave them options to choose from, 
by way of a poll. In this way, she could gauge the underlying assumptions of the audience and 
use this as a discussion point. This enabled her to deflect attention away from focusing too 
heavily on the participants of the study and enabled her to discuss with the audience the 
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rationale for their assumptions; bringing the focus more to the audience, while still illustrating 
the excellent uptake and engagement in the study (Brookfied and Preskill 1999). Importantly, 
the author had carefully created and delivered information in language that was accessible to 
all for dissemination in this setting. No medical or research language was used, as consistent 
with recommendations for dissemination of material in an accessible language appropriate to 
the audience; outlined as a quality of leadership by the NHS Leadership Academy (2013) and as 
recommended by INVOLVE (2015) and Reed (2018). Again, this illustrates the need for 
flexibility in delivery of the message for different audiences (McGuire 2001). Unknown to the 
author prior to and during the show, a reviewer from the Lancet was present in the audience. 
He introduced himself to the author at the end of the show and subsequently published his 
review in the Lancet: Gastroenterology and Hepatology (Appendix 15).  
On completion of the study, the author arranged a feedback session at the research venue in 
the hope of attracting some of the original participants. This is in line with the values of respect 
and transparency, as outlined in the principles of public engagement in research, suggested by 
the National Institute of Health Research (INVOLVE 2015) and was arranged to demonstrate 
the author’s concern for participants and the importance she and the research team placed on 
their feedback. Several service users attended, and this session was conducted in a very 
informal way, with the author sitting with them around a table with some snacks she had 
provided. The purpose of this was to create an atmosphere where the service users felt as 
comfortable as possible (Reed 2018). Often this group have poor experiences of dealing with 
health professionals (Watt 2013) and the author was keen she conducted this session with 
them as equal partners. The author presented a poster of the study to them and invited 
discussion. While the service users listened to the feedback regarding the study it became clear 
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to the author that they had questions to ask regarding their own liver health as many of them 
were attending the recovery centre for alcohol related issues. At least two of the participants 
expressed concerns regarding their own personal health, which the author was keen to discuss 
in a more personal face-to-face setting to enable confidentiality (NMC 2015). As a direct 
consequence of this feedback session, the author organised a general liver health session for 
one of the recovery groups held within the centre, where topics on liver health could be 
discussed in more general terms; an example of the impact on the recovery centre of 
dissemination of the results. Further examples of the impact of dissemination will be discussed 
later in this chapter. 
In order to disseminate the results of the study to a professional audience, the author devised 
abstracts for application to both medical and nursing conferences. She was successful in 
securing a poster (Appendix 16) presentation, on the 21st June 2016, at the medical conference 
organised by the British Society of Gastroenterology as part of the Digestive Disorders 
Foundation conference in London in 2016. Subsequent to this the abstract was published in the 
BMJ supplementary edition of GUT (Matthews et al 2016). The author was successful in 
securing an oral presentation at the local Nursing, Midwifery and Allied Health Professional 
Conference in Edinburgh (2018) and an oral presentation to the Royal College of Nursing 
International Research Conference in Birmingham on the 16th April 2018. Thereafter the 
manuscript submitted to the Journal of Clinical Nursing was accepted in March 2018 (Appendix 
17) and subsequently published in September 2018 (Matthews et al 2018). 
4.03 Impact of Screening  
As discussed, earlier in this chapter, representation of key stakeholders is an important 
principle in ensuring the impact of research Reed (2018). In considering the impact of this 
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research study, the author aimed to ensure, from an early stage, that she represented views of 
key stakeholders in the study design, through the initial meetings with her clinical lead, NHS 
management and management of the alcohol support centre. It has been demonstrated, in 
Chapter 2: Methods, that staff within the centre demonstrated coherence, cognitive 
participation, collective action and reflexivity; the key characteristics of Normalisation Process 
Theory where normalisation is the willingness to integrate a new intervention into everyday 
practice (May 2015). Staff demonstrated coherence, in being able to describe the intervention 
and an awareness of its purpose. They demonstrated cognitive participation, in engaging and 
participating in their role. Collective action where they engaged with the intervention as a 
group and reflexive monitoring where they felt there has been benefit to both them and their 
patients in hosting and recommending the intervention were also demonstrated (May, Sibley 
and Hunt 2014, Murray et al 2010). This is also consistent with the principle of engagement for 
impact in research (Reed 2018). Through involving staff from an early stage in the study design 
and gaining their support for the intervention, the author ensured engagement in the process. 
In addition, the author she maintained regular contact with staff, in a less formal and more 
social way in order to ensure regular feedback regarding the study consistent with 
recommendations by Reed (2018). Through joining staff for lunch or having coffee and, on 
occasion, bringing cake to share with them she was able to communicate with them in their 
comfort zone; ensuring she spoke in language familiar to them rather than using medical or 
research jargon (NHS Leadership Academy 2013). As Reed (2018) suggests, demonstrating that 
she was truly listening to staff and behaving in an approachable manner at all times was 
important in developing a respectful culture; one where communication was facilitated in an 
inclusive environment. This enabled the author to react promptly to any possible negative 
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feedback, had there been any. Subsequently, through dissemination of the results of the 
research study to a range of audiences, including key stakeholders, she received positive 
feedback and a great deal of encouragement for taking this initiative forward as a possible 
service development.  
In their competency framework for working in liver disease, the RCN (2015) suggest that all 
nurses, regardless of clinical background have skills and talents to integrate liver health into 
routine clinical practice. Public Health England’s “Make Every Contact Count” agenda (PHE 
2016) suggests that nurses are integral in making an impact on liver disease through discussion 
of possible risks and lifestyle choices to improve liver health. In addition to alcohol intake, 
healthy eating, keeping to a healthy weight and being physically active are deemed to be three 
of the lifestyle issues which can make the greatest improvement to an individual’s health and, 
as such, are factors which should be included in every patient contact, according to PHE (2016). 
This is also in line with the Scottish Government’s “2020 vision” where a strong focus on 
prevention, anticipation and supported self-management is recommended in order to improve 
the health of the nation (Scottish Government 2017) and the NHS Scotland Healthcare Quality 
Strategy (NHS Scotland 2010) which emphasises the use of the most appropriate interventions 
and supports in providing quality healthcare. This suggests, therefore, that in the context of an 
alcohol support centre and with appropriate training, nurses are well placed to deliver not only 
liver screening but more general lifestyle discussion to a group at high risk of liver and other 
chronic disease through their alcohol intake and obesity levels.  
In order to progress the research study to a service development it was clear that there were 
several considerations and challenges to overcome. Whilst NHS management agreed time for 
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the duration of the research study, lack of continued time resource meant this could not be 
sustained. As discussed, one limitation of this study was the small sample size. Whilst this was a 
convenience sample in this time-limited research, it would require a much larger sample size to 
be representative of the population and to give confidence in taking the research findings 
forward to a service development (Hack and Gwyer 2013). In addition, it was outwith the scope 
of the study to measure sustained lifestyle change, in relation to continued drinking.  However, 
the results were promising in terms of the uptake, the incidence of previously undiagnosed 
liver disease and the engagement, at six months following the FibroScan®, for those who 
required onward referral to specialist services. As support for the idea of taking the research 
forward to development grew, it became clear that the author needed to take a decision on 
two options. One option was to apply for funding for a longitudinal and larger piece of 
research, to explore the areas outwith the scope of this small study as recommended earlier in 
this chapter and delay any service development until more conclusive evidence was available. 
Another option was to take a pragmatic stance in harnessing the support, while it was still 
current, for screening provision by the staff at the recovery centre and creating an innovative 
way for this her to provide this. This option would not preclude any decision to take the 
research forward to a larger, longitudinal study. The author was aware that relationships 
between researchers and those communities where they carry out research often depends on 
what the researcher does next (INVOLVE 2015). Communities who host research can perceive 
that researchers may only value their collaborative relationship whilst it is of immediate use to 
their research (Reed 2018). In this respect, the author did not want to risk harming a continuing 
relationship with these staff by halting any screening provision when the staff felt so strongly 
that it was of immediate benefit to their service users. It was decided to take the risk that by 
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obtaining further data, albeit not collected under research conditions, the case for taking it 
forward as a service development and larger study would be strengthened. There are another 
three similar recovery centres in this city within the South of Scotland, where the service 
should also be offered, if it was to continue as an embedded and sustainable service. At this 
point it was not feasible for screening to be offered in these sites due to resource capacity 
(Schell et al 2013). In order to achieve this, further funding would be required which would 
require further work in gathering the necessary evidence and presenting a business case to the 
relevant NHS and Scottish Government executives. 
In view of the motivation from recovery staff for continuing screening the author’s decision 
was to negotiate for support from her own NHS management to explore pragmatic strategies 
for continuing this as a small-scale service development, or short-term project, in the first 
instance. The author gained support for a short-term project, with an initial timeline of six 
months. Management of the alcohol support centre, the original research venue, offered to 
host the screening as before. They agreed the use of the therapy room for screening, as was 
the case for the research study. 
At this time, the Scottish Government published an update of the Sexual Health and BBV 
Framework (Scottish Government 2015). In this version, they introduced the aim of increasing 
BBV testing in the population of those drinking to harmful levels. The rationale for this being 
that it was common for those who use drugs to change their substance of choice in time 
(Scottish Government 2015). Many of those who have injected drugs in the past, with the risk 
of BBVs this confers on them, may have changed from using drugs to using alcohol in time 
(Scottish Government 2015). Through her professional network, the author commenced 
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negotiation with the local BBV community team. The aim of these discussions was to negotiate 
whether, in the hope of replicating the good uptake seen in the study, it may be possible for 
this team to increase their contact with those drinking to harmful levels through offering 
screening for liver disease using the FibroScan® device, in addition to offering them a BBV 
screen at their attendance. This, therefore, would be consistent with the aims of the new 
framework (Scottish Government 2015). Through dissemination of the study results, the BBV 
team were aware and supportive of the original research study, making it easier for the author 
to engage (Reed 2018) them in discussion regarding the possibilities of taking it forward as a 
project. In so doing, the pathway and data collection strategy for the research study would 
need to be adapted to reflect the additional aims of the BBV team and ensure consistency, 
between members of the team (Schell et al 2013).  
Each member of the BBV team agreed to offer screening using the FibroScan® device, while in 
the study this was solely offered by the author. In this respect, the pathway for participants in 
this project (Appendix 18) differed from that used in the screening study (Appendix 13). 
Through negotiation with her management and those at the alcohol support centre, it was 
agreed that the liver outreach clinic, offered by the author for the research study, would accept 
referrals from this screening project, in order that those with a raised scan could be referred to 
her, as Hepatology Nurse Practitioner, for further initial assessment. Participants, with a 
FibroScan® result ≥7.1kPa would be referred to this clinic for further assessment. At this point, 
the pathway followed that of the original research study, with those participants with a 
FibroScan® result ≥7.1 kPa being seen by the author for further assessment with blood tests. 
Discussion of the results took place with the Consultant Hepatologist and onward referral 
arranged if necessary. Those with a scan result ≥8kPa were offered an assessment ultrasound 
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of the liver and an appointment with a Consultant Hepatologist, or Registrar, in the acute 
setting; as was the case in the original research study.  
Through discussion with the BBV team, amendments were made to the original data collection 
tool to include more in-depth data regarding participant’s potential risks of BBVs and where, if 
at all, they had accessed BBV screening in the past. This was important in determining whether 
this group was, indeed, hard to engage in BBV screening. In addition, and in an attempt to 
ensure standardisation in the alcohol history section of the tool, further amendments, were 
made; in particular the patterns of drinking were stated on this tool, in order that they were 
reported as either “daily”, “binge” or “intermittent” (Appendix 19).  With only one person 
collecting this data in the study inter-rater reliability (Hack and Gwyer 2013) was not an 
immediate concern. While this project was not conducted under research conditions, with 
three members of the BBV team carrying out the assessments it was important to ensure 
clarity and uniformity in, where possible. The assessment of participants continued in a 
focused, systematic manner, as was the case in the research study (McGee 2003). 
In offering this screening, it was imperative that the team were proficient in the use of the 
FibroScan® device. The author organised the initial training offered by Echosens®, the company 
responsible for manufacturing the device. To date, this is the recognised and validated training 
each operator undergoes in order to use the device. In taking the lead for this initiative and as 
mentor for the BBV team in offering screening the author observed them performing five 
FibroScan® tests within the acute setting following their initial training. The purpose of this was 
to ensure the ensure BBV team felt competent in performing screening in the community as an 
autonomous practitioner through having the opportunity for situational learning (Gibbs 1988) 
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in using the FibroScan® device on patients in a supported clinic. The members of the BBV team 
were able to maintain their competencies in the use of the FibroScan® through commencing 
and continuing its use with their own patient group, in addition to its use in this project.  
As specialist nurses, the BBV team had good knowledge of the physiology and pathophysiology 
of the liver, especially in relation to hepatitis C. However, in being the first point of contact for 
participants in this project it was important that they had good knowledge of other possible 
presentations of chronic liver disease. In order to ensure clinical safety, the author agreed time 
with her nurse management to act as coordinator and supervisor for this project and the 
Consultant Hepatologist, who provided clinical mentorship for the author in the research study, 
agreed to provide clinical governance for the BBV team for the duration of the project. As the 
research study was developed by the author, she also assumed the role of educator for the BBV 
team in the data collection and assessment procedures. This took the form of case studies and 
discussion as consistent with student centred learning theory (Biggs and Tang 2011) where, as 
adult learners, the BBV team were invited to identify their own learning needs against the 
objectives of the intervention. The author invited the team to suggest topics for discussion in 
both group and individual meetings. In addition to this, they were encouraged to search for 
reference material appropriate to their learning needs and the author recommended Sargent 
(2009) as the current text for liver disease management. During both the individual and group 
meetings, the author presented typical case scenarios and, through discussion, worked with 
the BBV team to determine how best to manage the participants in the scenario. This is 
consistent with adult learning theory, where the students are in charge of their own learning 
(Hughes and Quinn 2013). Opportunities for learning, through discussion (Brookfield and 
Preskill 1999) were facilitated by the author, in these sessions. In addition, through learning 
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from each other’s learning in this discussion the BBV team was given the opportunity for 
vicarious learning (Jacques and Salmon 2007). Following these groups and individual teaching 
sessions, individual members of the BBV team were given the opportunity for situational 
learning (Biggs and Tang 2011) when they were invited to sit in and observe a liver clinic run by 
either a Consultant Hepatologist or Senior Registrar. This gave the BBV team the opportunity to 
observe the management of patients with complications of liver disease they were not likely to 
see in their current practice. While there was no expectation for them to manage complications 
of liver disease during the screening project, the rationale for this was to enable them to 
recognise such complications, should a participant present with them, and improve their 
confidence in appropriate referral to liver services of such individuals. In addition, the BBV 
team was subsequently invited to shadow the author in carrying out at least one screening 
clinic. Through situational learning (Biggs and Tang 2011) this enabled them to see the 
relevance of their learning by observing the consultation and screening in action and being 
given the opportunity to ask questions between consultations. Further opportunities for 
learning included opportunities to observe the nurse led cirrhosis surveillance clinics within the 
acute sector and the nurse led liver outreach clinic within the alcohol support setting. Through 
observation of these clinics, the BBV team was able to observe the participant pathway in 
action as any participant with a raised FibroScan® reading were referred to the liver outreach 
clinic. Thereafter, should they be diagnosed with cirrhosis, they would enter into cirrhosis 
surveillance; as carried out at these nurse led clinics. Observing these clinics therefore would 
also enable the BBV team to describe the full pathway to participants.  As their learning 
progressed, the BBV team members were then in a position to offer the screening consultation 
whilst observed by the author who had devised competency sheets (Appendix 20) in order to 
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provide feedback to the individual members. At the point when both the author and each 
individual member of the BBV team considered themselves to be competent in the screening 
process and happy with the escalation process should a participant attend showing signs of 
liver decompensation, the BBV team member were “signed off” as competent and able to offer 
screening without immediate supervision. Importantly, as registered nurses, the BBV team 
were responsible for ensuring they worked within their level of competency and scope of 
practice (NMC 2015). Their involvement with this project had been agreed with their manager 
and, with the publication of the updated version of the Sexual Health and BBV Framework 
(Scottish Government 2015) their scope of practice had been extended to include those 
drinking to harmful levels.  However, for the duration of the screening project, the author 
continued to offer clinical supervision to each member of the BBV team, provided further 
assessment of those with a raised FibroScan® result and coordinated attendance of those 
requiring onward referral to specialist services.    
It is important to note that, as the author and the BBV team members were senior nurses with 
years of experience working in their respective fields, this learning was not a one-way process. 
Consistent with knowledge exchange, as defined by Reed (2018), knowledge was actively 
shared between the BBV team and the author, with the author taking advice and learning from 
the BBV team regarding the BBV aspect of screening. This was in contrast to knowledge 
transfer, where knowledge passes in one direction from perceived expert to novice (Reed 
2018).  
In order to devise the escalation procedures, the author worked collaboratively with the BBV 
team. It was important they felt clinically and educationally supported in this new role, and 
95 
 
that, while screening for liver disease was a novel intervention for them it was important that 
their confidence and competence in carrying out this work was comparable to the standard of 
the research study (Schell et al 2013), prior to commencing the project. One main difference 
between this project and the research study was that the author designed and ran the study; 
taking clinical advice, where necessary from the Consultant Hepatologist on her research team. 
In this project, the BBV team was offering screening under supervision from the author who 
conducted triage of patients with when the BBV team had queries regarding their 
management. The author, in this case managed the project (Dwyer, Stanton and Thiessen 
2004) and acted as an intermediary between the BBV team and her medical colleagues; 
creating a link between community and the acute setting. 
Schell et al (2013) devised a framework for sustainability of new services that include funding 
stability, political support, organisational capacity, programme evaluation, public health 
impacts and strategic planning. At that time when the author experienced resistance from 
some of her nursing and medical colleague, she invested energy getting buy in from the staff at 
the recovery centre, her nurse management and the interested Consultant Hepatologist, who 
subsequently became part of the research team. As a research study, it was not necessary for 
her to go beyond the permissions she required from her management and the ethics 
committee. However, since completing the research study the clinical lead has changed from 
the Consultant who supported the research study to the Consultant who initially felt that, by 
carrying out the study, the author was “looking for work”. While this has not stopped the 
project running to completion, there had been some initial resistance from members of the 
medical team, including the current clinical lead, in the project being taken forward. This 
resistance was similar to that experienced at the start of the research study.  It is possible 
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therefore, that if the author had invested more time and strategic planning in enlisting the 
support of these colleagues from early on in the research process, they may have offered less 
resistance at the stage of further rolling it out for the project and subsequent service provision 
across all recovery centres in the city. Through involving a wider range of Consultants, at that 
stage, the author could have ensured more representation from possible stakeholders. In this 
way, there would have been more individuals with a personal or professional interest in the 
success, or otherwise, of the venture and may have ensured more support at the project to 
service development stage. Knowing the powerful individuals in an institution and getting them 
onside early on can help the sustainability of the research. While the author had identified the 
powerful individual, who could help her take the research forward, at that time, she did not 
fully appreciate the political environment, nor could she have anticipated that the power 
dynamics may change in the way they did. While, this may have slowed progress there is 
indication now of support from the aforementioned colleagues in taking this forward as a 
service development at a time when the follow-on project is currently under evaluation. The 
author is currently negotiating with senior medical colleagues and other interested parties 
within Public Health and nurse management, in advance of building a business case.  
4.04 Advancing Clinical Practice 
O’Connell, Gardner and Coyer (2014) emphasise the importance of capability in advancing 
practice i.e. the ability to manage change, be flexible and move beyond competency. In 
developing this study, where potential participants may drop in rather than work to pre-
arranged appointments, capability would be a requirement in order that the nurse can work 
confidently and autonomously in what could be an unpredictable environment. In their concept 
analysis, Dowling et al (2013) highlighted the common themes relating to advanced nursing 
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practice, which include clinical expertise, leadership, autonomy and role development. While 
advanced nursing practice is often seen as the adoption of a more medical focus through role 
extension (Dowling et al 2013), role expansion is a key feature of advanced practice through 
the advancement of the core nursing skills of clinical practice, research, education and 
leadership (Rolfe 2013). Health Education England (HEE 2019) further defines advanced clinical 
practice as a practitioner working with a high degree of autonomy, analysis of complex 
problems and decision making. In identifying the gap in service provision and having the 
courage to challenge beyond her remit, the author demonstrated self-confidence in her ability 
to question the status quo and resilience in continuing to challenge and promote her idea for 
developing the innovation as a research study. Ultimately, the author recognised the potential 
benefits of the innovation to patients and strove to achieve this, despite the resistance she 
experienced. This is consistent with the first of the nine dimensions of NHS Leadership 
Academy’s “Inspiring Shared Purpose” (NHS Leadership Academy 2013) where challenging 
beyond her remit for the benefit of the service she displayed this value at exemplary level (NHS 
Leadership Academy 2013).  
Recognising the resistance from her nursing colleagues became a pivotal point in the 
development of the author’s leadership skills, as it was a demonstration of how her behaviour 
was affecting other members of the team. While resistance to change from immediate 
colleagues is common in taking any project or innovation forward (Dwyer, Stanton and 
Thiessen 2004) this was emerging into an escalating conflict situation (Proksch 2016), with, in 
the author’s perception, attempts being made to publicly damage her image. For her part, the 
author was aware she was starting to de-personalise these opposing colleagues to status akin 
to that of opponents in a competition which needed to be won. It could be argued that, in this 
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respect, the conflict could also be a driver for the development of the innovation (Proksch 
2016) but, this would only be to the advantage of the “victor”. According to the escalation 
model for conflict which progresses from the “Resentment phase” to “Exchange of blows” to 
“Destruction” this conflict was reaching the “Exchange of blows” level. In this respect, the 
conflict was becoming destructive and was set to risk, not only the development of the 
innovation but the whole team dynamics and personal welfare of both the author and her 
opposing colleagues (Proksch 2016). 
It became clear to the author that it was important to harness a positive attitude towards the 
study from immediate colleagues, where possible, to protect her own and others’ emotional 
wellbeing throughout this process. In order to improve relations with fellow teammates, the 
author requested a facilitated meeting with a member of her team, who seemed most 
resistant, and their manager. The aim of this meeting was to discuss any issues surrounding the 
development of this innovation in a safe space where both author and colleague could ensure 
their views were heard, as suggested by Proksch (2016). It was considered that this should 
reduce the possibility of an emotional escalation, which was becoming typical of 
communication between the two, at that time. This in itself, demonstrated leadership qualities 
on the part of the author, in taking responsibility for caring for herself and the team consistent 
with “Leading with care”, as outlined by the NHS Leadership Academy (2013). This also served 
to improve the author’s self-awareness, in particular, realising that her approach could, at 
times, be seem as “dogmatic” by some members of the team. Incidences referred to were 
remembered by the author as times when she felt under attack by members of the nursing 
team concerning the study and, in her opinion was acting defensively. In this respect, meetings 
with members of the nursing team were helpful in enabling more self-awareness with regard to 
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how her behaviour may be perceived by others and enabled her to work to improve this for the 
future.  
In order to progress the study, the author worked to improve her communication skills to 
ensure clarity and transparency as suggested by Reed (2018). She presented the study to the 
liver unit, as discussed in Chapter 1: Introduction, and developed ongoing communication 
strategies; presenting updates to the team at nurse meetings and periodically emailing short 
progress reports to the wider team, the author demonstrates strategies consistent with the 
NHS Leadership Academy’s “Sharing the vision” dimension of leadership (NHS Leadership 
Academy 2013).   
Through sharing her expertise with the BBV community team and supporting the development 
of their capability in devising a course of education to support the assessment process for the 
project, where none currently existed and in designing, developing and facilitating this learning 
the author displays qualities consistent with the pillars of advanced clinical practice, in 
particular, that of leadership, research and education, as defined by Health Education England 
(HEE 2019).  
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Chapter 5: Conclusion 
5.01 Conclusion of Study Findings and Suggestions for Further Investigation 
The author designed this study and sought support in its development from both clinical and 
academic collaborators after identifying a need, within an area of her work, for earlier 
identification of liver disease and creating an opportunity to respond in an innovative way by 
the use of a portable FibroScan® device as the primary screening tool. She targeted a cohort of 
service users, accessing a community alcohol support service, drinking alcohol to harmful levels 
and therefore at high risk of liver disease.  These service users, who were considered hard to 
engage in mainstream services (Watt 2013), were not currently under her care and, prior to the 
research study, had no recognised pathway to specialist services other than referral by their 
GP. This chapter summarises the study results with links to current literature in this area, 
where possible and suggests recommendations for taking this work forward.  
This prospective observational study was developed with the aim of determining the viability of 
a service providing screening for liver disease, with a portable FibroScan® device. The 
objectives of this study were to a) record the uptake of a FibroScan® in individuals accessing 
one community alcohol support service, b) determine the prevalence of undiagnosed 
significant liver disease in a self-selected, convenience sample of individuals accessing one 
community alcohol support service and c) to report attendance at six months following referral 
to specialist liver services, of those participants referred with a FibroScan® reading ≥ 7.1 kPa. 
Through pursuing these study objectives, the results of this study suggest a positive answer to 
the research question “Can a portable FibroScan® device be an acceptable tool for cirrhosis 
screening in a community alcohol support service?” and confirming the original hypothesis that 
it would be acceptable. 
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In designing this study, within the limitations of budget and time resource, complex 
intervention theory was consulted (MRC 2008) and, in line with the author’s pragmatic stance, 
the concept of practical effectiveness was utilised in taking this study forward. The author 
successfully engaged the multi-agency team working in the alcohol recovery centre, in order to 
progress the study, in line with Normalisation Process Theory (May 2015), where staff find the 
intervention easy to describe (coherence), they engage and participate in their role (cognitive 
participation), engage with the intervention as a group (collective action) and feel there is a 
benefit to both them and their patients (reflexive monitoring). 
Through a convenience sampling recruitment strategy, this study targeted those accessing a 
community alcohol support centre, who were concerned about the effects of their past or 
present drinking on the health of their liver. This self-selected group were then offered a 
FibroScan® test. An alcohol history and other demographic data was collected using the 
focused assessment data collection tool developed by the author specifically for this study. This 
demographic data focused on conditions, which could either increase the participant’s risk or, 
in some cases, be a clinical feature of chronic liver disease. These include BMI, metabolic 
syndrome, diabetes, family medical history in first-degree relatives and history of alcohol 
excess in the immediate family (Muir 2015).  
Acceptability in a healthcare intervention can be anticipated when participants consider it to be 
appropriate, an important factor when considering uptake or participation in a healthcare 
intervention (Sekhon, Cartwright and Francis 2017). In this respect, an uptake of 67% of those 
informed of the study suggests that cirrhosis screening, using a portable FibroScan® device, in 
the outreach setting of a community alcohol service in an area of high deprivation is 
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acceptable. This is consistent with the findings of Foucher et al (2009) and Marshall et al 
(2015), who found community screening for liver disease with a FibroScan® device in a cohort 
of participants who injected drugs to be acceptable, as discussed in the literature review. 
After scanning, 26% (20/76) of participants with a reliable result had a FibroScan® ≥7.1kPa 
requiring referral on to the nurse led clinic. While not directly comparable, due to the 
difference in threshold for referral to the nurse clinic, this finding is generally consistent with 
the outcomes of the study conducted by Harmen et al (2015). This study, as previously 
critiqued, also targeted a high risk population for liver disease for screening and, with a 
threshold of 8ka, found that 26.8% (98/366) of his cohort required onward referral while 
Roulot et al (2010) , also with a threshold of 8kPa, found that only 7.5%  (89/1190) of his 
general population cohort required onward referral. The results of this study, therefore, further 
suggest that targeting a population at high risk of liver disease may be more efficient than 
offering a general population screening initiative. 
Of the 20 participants requiring onward referral, in this study, 20/20 (100%) engaged in further 
assessment. Of those, 12 required onward referral to specialist liver services. Subsequent 
compliance with specialist services in this sample (n=12) was ≥ 90%. In evaluating this, using 
health behaviour theories such as Self-Efficacy (Bandura 1997),  The Health Belief model 
(Skinner, Tiro and Champion 2015) and the Theory of Planned Behaviour (Montaño and Kasprzyk 
2015), this level of engagement displays positive signs of motivation and intention to engage in 
a cohort initially considered hard to engage. This is a positive predictor for longer-term positive 
lifestyle changes such as reduction of alcohol intake and long-term engagement in specialist 
follow up. However, it was outwith the scope of this study to establish whether lifestyle 
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changes were sustained beyond the six-month follow up period, after onward referral. A 
further, longitudinal study is recommended in order to examine this. 
This was a timely innovation, linking well with recent drivers such as The Lancet Commission’s 
“Addressing liver disease in the UK…” Williams et al (2014) who developed ten key 
recommendations, one of which was to “Improve support services in the community setting for 
screening of high-risk patients”. This recommendation acknowledges the impact of health 
inequality on liver disease and is consistent with findings from the study by Thurnheer et al 
(2015) where they found a higher prevalence of liver disease outwith tertiary settings, 
indicating that mainstream health care in liver disease was not reaching those at highest risk. 
This is also consistent with recent data where, in 2015, mortality rates from CLD in Scotland in 
the most deprived decile were six times those of the least deprived (34 v 6 per 105) and 
morbidity rates were five times higher (435 v 88 per 105) (ScotPHO 2017).  The results of this 
screening study, therefore, suggest this could offer one option for engaging patients at high-
risk of liver disease, through harmful alcohol consumption, in screening for liver disease 
attending a community alcohol support centre with a catchment area including areas of high 
deprivation.  
The World Health Organisation (WHO) (2011) pledged to address health inequalities through 
developing strategies to promote effective partnerships with health and other sectors in 
achieving health through policies and actions on social determinants of health, specifically 
targeting vulnerable and high-risk groups. In Scotland, the Public Bodies (Joint Working) 
Scotland Act (Scottish Government 2014) introduced a statutory duty for NHS Boards and 
Councils to integrate planning and delivery of health and social care services, strengthening the 
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Scottish Government’s commitment to community-based anticipatory care (Audit Scotland 
2015). This care is to be provided jointly between the NHS, statutory and non-statutory social 
care providers with the aim of reducing the number of patients with long-term conditions being 
admitted to acute services (Audit Scotland 2015). This initiative is an excellent example of 
health and social care integration, with the NHS and third sector working together with the 
shared aim of enhancing patient safety through facilitated screening for liver disease in a multi-
agency community setting. In this setting where potential participants were attending for 
support in alcohol reduction, staff worked towards a common aim for with the aim of providing 
low threshold access to specialist services for patients considered, by support staff in the 
recovery centre, to be hard to engage in mainstream services. 
Through successfully pitching for funding for the rental of the portable FibroScan® device to an 
audience of senior executives from NHS Lothian, the Scottish Government and private industry 
the author has utilised high-level negotiation and leadership skills (NHS Leadership Academy 
2013). Though overcoming resistance to the research from some colleagues she has developed 
and demonstrated resilience in taking this study forward. As a consequence of developing and 
the use of excellent negotiating skills, she secured buy in from some senior medical colleagues, 
NHS management and non-statutory management within the alcohol recovery centre in 
supporting this initiative and is an excellent example of collaborative working, as consistent 
with the aims of the recent government strategy in health and social care integration (Scottish 
Government 2014). The author recruited support from a senior medical colleague and 
academic collaborator, in developing a research team, of which she was Principal Investigator. 
This demonstrated key project management skills (Dwyer, Stanton and Thiessen 2004), where, 
as the most junior member of the team in her professional capacity, she was, for the duration 
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of the study, responsible for designing, leading, evaluating the study with the support of their 
clinical and academic expertise. In addition to this, she was responsible for disseminating 
information on the study to a range of audiences with, as Principal Investigator, the 
responsibility for writing the material for the abstracts and manuscripts submitted for 
publication with editorial rights to this written content. 
In creating enthusiasm and securing buy in from key stakeholders in taking forward the findings 
from the study forward to a project where screening is offered by members of another team 
the author has further developed her leadership skills. Supporting the BBV team to build on 
their capacity to deliver this screening through developing training and supervision, 
demonstrates her skills in education; another pillar of advancing clinical practice (HEE 2019).  
This innovation has demonstrated it can identify significant liver disease in the targeted 
population and results indicate a high level of early engagement in NHS liver services in a 
cohort who are drinking to harmful or hazardous levels; previously considered hard to engage 
(Watt 2013). Nurse led screening in this setting provides an opportunity for education and 
discussion regarding lifestyle factors in liver disease with a cohort who seem motivated to 
improve their liver health. Further work is needed to optimise this intervention to understand, 
more fully, what are the essential active components necessary to replicate this outcome 
(Levati 2016, Sermeus 2015). This study demonstrates advanced nursing practice in the area of 
Hepatology through the implementation of this innovation in screening for liver disease with a 
portable FibroScan® device in a group considered hard to engage. 
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Appendix 3: Innovation Event Voting Slide 
 
P3:This proposal is an innovative approach for NHS
Lothian which supports the delivery of safer, more
effective and patient centred services.
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Appendix 12: Table Showing Fibroscan, Blood and Ultrasound 
Results for Participants Requiring Onward Referral 
 
 
Fibroscan 
Result 
ALT AST AST/ALT Hyaluronic 
Acid 
Platelets USS 
CS04 7.7 63 34 0.54 13.51 290 N/A 
CS06 7.9 33 71 2.15 52.38 164 N/A 
CS07 21.8 131 107 0.82 482.76 122 Spared 
parenchyma 
neg on MRI 
CS13 7.6 16 25 1.56 31.53 319 N/A 
CS19 7.6 25 23 0.92 47.49 226 N/A 
CS20 10.5 53 84 1.58 276.29 227 Cirrhotic 
appearance 
CS22 8.8 36 45 1.25 27.7 232 Fatty 
infiltration 
CS23 8.7 81 33 0.41 98.65 225 Fatty 
infiltration 
CS38 11.1 59 85 1.44 16.73 184 Fatty 
infiltration 
CS41 7.6 10 22 2.2 35.22 346 N/A 
CS42 8 60 64 1.07 34.21 265 NAD 
CS47 7.4 15 22 1.47 13.95 148 N/A 
CS54 11.8 61 43 0.7 74.37 283 Fatty 
infiltration 
CS56 7.8 80 77 0.96 29.86 210 N/A 
CS58 13.9 92 77 0.84 137.52 293 Fatty 
infiltration 
CS62 32.4 19 110 5.78 206.05 172 Cirrhotic 
CS64 56.1 65 96 1.48 189.65 124 NAD 
CS67 10.3 52 38 0.7 47.03 261 Fatty 
infiltration 
CS71 19.8 50 81 1.6 >800 115 Fatty 
infiltration 
CS72 7.9 17 22 1.29 16.73 249 N/A 
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Appendix 14: Doctoral Conference Letter  
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Thank you again and I wish you well as you continue to progress with your studies.  
 
Kind regards 
Lindsey  
 
Dr Lindsey Defew BSc (Hons), PhD 
Graduate School Officer 
Division of Governance and Quality Enhancement 
QMU, Musselburgh, East Lothian, EH21 6UU 
graduateschool@qmu.ac.uk  
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Appendix 16: Poster Presentation for BSG 
Cirrhosis Screening with a Portable 
Fibroscan® Device in a Community 
Alcohol Support Service Feasibility Study
Karen Matthews1,2, Alastair MacGilchrist1, Margaret Coulter Smith2, Roseanne Cetnarskyj3,
1 = Royal Infirmary of Edinburgh; 2 = Queen Margaret University; 3 = Glasgow Caledonian University
Introduction
Alcohol misuse is the major cause of the increase in deaths from liver disease in 
the UK1, particularly in Scotland2 and particularly in areas of social deprivation. 
Liver disease usually presents late, with advanced liver disease and cirrhosis often 
asymptomatic3. Patients with alcohol misuse in areas of social deprivation are a 
“hard to reach” population. This study assessed the feasibility of using a portable 
Fibroscan® to measure transient elastography (TE), a non-invasive method of 
assessing hepatic fibrosis, as a screening tool within a community alcohol support 
service. The study monitored the uptake of a Fibroscan® in individuals accessing 
one community alcohol support service in a deprived area; determined the 
apparent prevalence of undiagnosed fibrosis/cirrhosis in participants over a 6 
month period; and monitored engagement following referral to specialist liver 
services of those individuals with TE >7 kPa.
Method
The project was advertised at a drop-in centre in a deprived area of North 
Edinburgh for people with alcohol problems. individuals who self-identified as 
harmful drinkers and wished to have a Fibroscan were given information packs and 
invited back for a Fibroscan. Those with a TE ≤7kPa were given advice on alcohol 
and liver disease. Those with a TE >7kPa were referred to a nurse-led clinic within 
the community service for further tests, results of which determined onward 
referral to a liver specialist. Participants were monitored for compliance with 
appointments and follow-up interventions.
Results
118 research packs issued with 79 participants, an uptake of 67%. 3 Fibroscan® 
results were unreliable. 20 of 76 (26%) participants had a reading >7kPa requiring 
referral to nurse-led service. 12 (16%) with indications of significant liver disease 
requiring onward referral to liver specialist including 5 (7%) with suspected 
cirrhosis. Following medical assessment this increased to 6 (8%) with cirrhosis. 
19/20 (95%) participants requiring referral to nurse led service attended for further 
investigations. 11/12 (92%) participants requiring onward referral to specialist 
services attended initial appointment.
References
1.BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER AND BRITISH SOCIETY OF GASTROENTEROLOGY 2009. The National Plan for Liver Services. A time to act: improving liver health and outcomes in liver disease.
2.SCOTTISH PUBLIC HEALTH OBSERVATORY, 2015. Public Health Information for Scotland
3.WILLIAMS, R., et al 2014. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet. vol. 384, pp. 1953-1997.
8% 5%
1%
1%
11%
74%
Diagnostic outcomes
n=76
Cirrhotic (n=6)
Fibrotic (n=4)
Undiagnosed in nurse follow up (n=1)
Non fibrotic discharged (n=1)
Seen by nurse but no need for medical referral (n=8)
No onward referral (n=56)
Impact
A 67% uptake suggests a nurse led Fibroscan® service in a 
community alcohol setting, targeting a hard to reach population, 
is acceptable. Early indications show a high compliance with liver 
services offering potential for early intervention and improved 
health outcomes.
Engagement of 
those requiring 
onward referral 
Expected number Number attended
Attended nurse 
appointment at the 
Hub
20 19
Attended first 
medical 
appointment at RIE
12 11
Attended six month 
follow up 10 9
Attended abdominal
ultrasound 12 12
67%
33%
Uptake of Fibroscan
n=118
Participants (n=79) Non participants (n=39)
74%
10%
9%
7%
Fibroscan results
n=76
≤7kPa (n=56) >7kPa <8kPa (n=8)
≥ 8kPa <12.5kPa (n=7) ≥ 12.5 kPa (n=5)
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159 
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